AU2007249129A1 - Novel method for analysing phenotypic characteristics of human immunodeficiency virus (HIV) - Google Patents
Novel method for analysing phenotypic characteristics of human immunodeficiency virus (HIV) Download PDFInfo
- Publication number
- AU2007249129A1 AU2007249129A1 AU2007249129A AU2007249129A AU2007249129A1 AU 2007249129 A1 AU2007249129 A1 AU 2007249129A1 AU 2007249129 A AU2007249129 A AU 2007249129A AU 2007249129 A AU2007249129 A AU 2007249129A AU 2007249129 A1 AU2007249129 A1 AU 2007249129A1
- Authority
- AU
- Australia
- Prior art keywords
- seq
- stage
- hiv
- codes
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241000725303 Human immunodeficiency virus Species 0.000 title claims description 142
- 238000000034 method Methods 0.000 title claims description 32
- 108090000623 proteins and genes Proteins 0.000 claims description 127
- 230000003321 amplification Effects 0.000 claims description 117
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 117
- 102100034349 Integrase Human genes 0.000 claims description 112
- 241000700605 Viruses Species 0.000 claims description 105
- 230000001413 cellular effect Effects 0.000 claims description 97
- 238000004458 analytical method Methods 0.000 claims description 92
- 230000035772 mutation Effects 0.000 claims description 85
- 239000003550 marker Substances 0.000 claims description 73
- 230000003612 virological effect Effects 0.000 claims description 65
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 53
- 239000003112 inhibitor Substances 0.000 claims description 51
- 150000007523 nucleic acids Chemical class 0.000 claims description 50
- 230000001177 retroviral effect Effects 0.000 claims description 48
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 40
- 239000003153 chemical reaction reagent Substances 0.000 claims description 40
- 101710091045 Envelope protein Proteins 0.000 claims description 39
- 101710188315 Protein X Proteins 0.000 claims description 39
- 150000001875 compounds Chemical class 0.000 claims description 38
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 37
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 claims description 34
- 108091005804 Peptidases Proteins 0.000 claims description 34
- 239000004365 Protease Substances 0.000 claims description 34
- 239000002245 particle Substances 0.000 claims description 34
- 208000015181 infectious disease Diseases 0.000 claims description 30
- 101800001690 Transmembrane protein gp41 Proteins 0.000 claims description 24
- 108010061833 Integrases Proteins 0.000 claims description 19
- 208000036142 Viral infection Diseases 0.000 claims description 19
- 239000012634 fragment Substances 0.000 claims description 19
- 230000009385 viral infection Effects 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 16
- 230000003362 replicative effect Effects 0.000 claims description 15
- 238000001890 transfection Methods 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- 239000012472 biological sample Substances 0.000 claims description 11
- 239000000523 sample Substances 0.000 claims description 11
- 229940125777 fusion inhibitor Drugs 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 108020004705 Codon Proteins 0.000 claims description 9
- 230000010076 replication Effects 0.000 claims description 9
- 101710177291 Gag polyprotein Proteins 0.000 claims description 8
- 101710125418 Major capsid protein Proteins 0.000 claims description 8
- 238000001514 detection method Methods 0.000 claims description 8
- 101900297506 Human immunodeficiency virus type 1 group M subtype B Reverse transcriptase/ribonuclease H Proteins 0.000 claims description 7
- 238000011002 quantification Methods 0.000 claims description 7
- 230000029812 viral genome replication Effects 0.000 claims description 7
- -1 RNAse H Proteins 0.000 claims description 6
- 102000005962 receptors Human genes 0.000 claims description 6
- 108020003175 receptors Proteins 0.000 claims description 6
- 230000010415 tropism Effects 0.000 claims description 6
- 101710149951 Protein Tat Proteins 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims description 4
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 4
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 4
- 108010016183 Human immunodeficiency virus 1 p16 protease Proteins 0.000 claims description 4
- 108700020129 Human immunodeficiency virus 1 p31 integrase Proteins 0.000 claims description 4
- 108091027981 Response element Proteins 0.000 claims description 4
- 108010003533 Viral Envelope Proteins Proteins 0.000 claims description 4
- 108010030074 endodeoxyribonuclease MluI Proteins 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 210000004779 membrane envelope Anatomy 0.000 claims description 4
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims description 3
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims description 3
- 101710149136 Protein Vpr Proteins 0.000 claims description 3
- 101710201961 Virion infectivity factor Proteins 0.000 claims description 3
- 238000006471 dimerization reaction Methods 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 claims description 2
- 108700004026 gag Genes Proteins 0.000 claims description 2
- 101150098622 gag gene Proteins 0.000 claims description 2
- 230000006801 homologous recombination Effects 0.000 claims description 2
- 238000002744 homologous recombination Methods 0.000 claims description 2
- 229960001330 hydroxycarbamide Drugs 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims description 2
- 101150098557 mul1 gene Proteins 0.000 claims 2
- 241000894007 species Species 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 40
- 239000000047 product Substances 0.000 description 27
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 22
- 238000012360 testing method Methods 0.000 description 21
- 239000002773 nucleotide Substances 0.000 description 15
- 125000003729 nucleotide group Chemical group 0.000 description 15
- 239000013612 plasmid Substances 0.000 description 13
- 108091034117 Oligonucleotide Proteins 0.000 description 8
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 8
- 101710147327 Calcineurin B homologous protein 1 Proteins 0.000 description 7
- 101710205625 Capsid protein p24 Proteins 0.000 description 7
- 101710177166 Phosphoprotein Proteins 0.000 description 7
- 101710149279 Small delta antigen Proteins 0.000 description 7
- 102100022563 Tubulin polymerization-promoting protein Human genes 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 7
- 210000002381 plasma Anatomy 0.000 description 7
- 229960004748 abacavir Drugs 0.000 description 6
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000006798 recombination Effects 0.000 description 6
- 238000005215 recombination Methods 0.000 description 6
- 230000000798 anti-retroviral effect Effects 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000013207 serial dilution Methods 0.000 description 4
- UYYRDZGZGNYVBA-VPXCCNNISA-N (2s,3r,4s,5r,6r)-2-[2-chloro-4-[3-(3-chloro-4-hydroxyphenyl)-1,1-dioxo-2,1$l^{6}-benzoxathiol-3-yl]phenoxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(C2(C3=CC=CC=C3S(=O)(=O)O2)C=2C=C(Cl)C(O)=CC=2)C=C1Cl UYYRDZGZGNYVBA-VPXCCNNISA-N 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 3
- 108010005774 beta-Galactosidase Proteins 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229960003804 efavirenz Drugs 0.000 description 3
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 229960000689 nevirapine Drugs 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000001018 virulence Effects 0.000 description 3
- SPZFCKVVHXRLAI-XOCWCZJOSA-N (3s,4s)-4-[8-[[(1r,3as,5ar,5br,7ar,9s,11ar,11br,13ar,13br)-9-hydroxy-5a,5b,8,8,11a-pentamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-3a-carbonyl]amino]octanoylamino]-3-hydroxy-6-methylheptanoic acid Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CC[C@]1(C)[C@@H]2CC[C@@H]2[C@H]3[C@H](C(C)=C)CC[C@]3(C(=O)NCCCCCCCC(=O)N[C@@H](CC(C)C)[C@@H](O)CC(O)=O)CC[C@]21C SPZFCKVVHXRLAI-XOCWCZJOSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102100026189 Beta-galactosidase Human genes 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000012761 co-transfection Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 238000003205 genotyping method Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000002850 integrase inhibitor Substances 0.000 description 2
- 229940124524 integrase inhibitor Drugs 0.000 description 2
- 229960001627 lamivudine Drugs 0.000 description 2
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000017613 viral reproduction Effects 0.000 description 2
- 108010017088 CCR5 Receptors Proteins 0.000 description 1
- 102000004274 CCR5 Receptors Human genes 0.000 description 1
- 108010041397 CD4 Antigens Proteins 0.000 description 1
- 108010061299 CXCR4 Receptors Proteins 0.000 description 1
- 102000012000 CXCR4 Receptors Human genes 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 239000006144 Dulbeccoโs modi๏ฌed Eagle's medium Substances 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 241000940612 Medina Species 0.000 description 1
- 229940124821 NNRTIs Drugs 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical class C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 231100000673 doseโresponse relationship Toxicity 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 108700004025 env Genes Proteins 0.000 description 1
- 101150030339 env gene Proteins 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000012120 genotypic test Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000036632 reaction speed Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229960001203 stavudine Drugs 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Description
AUSTRALIA
Patents Act 1990 COMPLETE SPECIFICATION Standard Patent Applicants: INSERM and Eurofins Viralliance, Inc.
Invention Title: NOVEL METHOD FOR ANALYSING PHENOTYPIC CHARACTERISTICS OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) The following statement is a full description of this invention, including the best method for performing it known to us: la NEW METHOD FOR ANALYSIS OF THE PHENOTYPIC CHARACTERISTICS OF THE HUMAN IMMUNODEFICIENCY VIRUS (HIV)
O
The entire disclosure in the complete specification of our Australian Patent Application No. 2002223052 is by this cross-reference incorporated into the present specification.
All references, including any patents or patent applications, cited in this specification are hereby incorporated by reference. No admission is made that any reference constitutes prior art. The discussion of the references states what their authors assert, and the applicants reserve 10 the right to challenge the accuracy and pertinency of the cited documents. It will be clearly Sunderstood that, although a number of prior art publications are referred to herein, this reference C=K, does not constitute an admission that any of these documents forms part of the common general knowledge in the art, in Australia or in any other country.
In the claims which follow and in the description of the invention, except where the context requires otherwise due to express language or necessary implication, the word "comprise" or variations such as "comprises" or "comprising" is used in an inclusive sense, i.e.
to specify the presence of the stated features but not to preclude the presence or addition of further features in various embodiments of the invention.
This invention relates to a method for analysis of the phenotypic characteristics that certain virus stocks, in particular the HIV virus, exhibit.
Genotypic tests that are quick and widely available for detecting the presence of mutations in viral genes have been developed, for example, for detecting mutations that are present in the genes that code for the protease or the reverse transcriptase of HIV.
Although certain mutations have been associated with a particular inhibitor of viral activity, others are associated with treatment by several molecules. In addition, with the development of new inhibitor molecules, the genotyping of virus variants that defy treatment becomes increasingly complex. This makes difficult the evaluation and the fact of knowing for which inhibitors the viruses become resistant or still preserve a slight susceptibility. Under these circumstances, the presence and the accumulation of resistance mutations can surely constitute a good index of the evolution of the resistance, but the simple detection of these mutations on the genotypic level is no longer adequate for evaluating quantitatively the resistance level, a parameter that proves crucial for optimizing the therapeutic orientations of patients with whom antiviral therapy fails.
N \Mejboume\Cases\Patent\49000-4999\P49475 AU I\Specis\P4S47SAU.I SpccifAiiaon 2007-12.14.doc 14/12/07 -lb The phenotypic characteristics of the viruses are linked to various aspects of viral behaviour and are directly involved in numerous interactions between said viruses and their environment.
N \Melbounc\CasesPatnt\490OO499919\J'4947S.AU. I\Specis\P49475 AU. Specification 2007-12-1I4.doc 14/12/07 Only the phenotypic tests, which measure directly in the culture medium the Smodification of the phenotypic characteristic of the virus, such as the inhibition of the Sviral activity, for example in the presence of inhibitor compounds of said viral activity, provide a quantitative index of the resistance.
Other phenotypic characteristics of which analysis proves interesting, in particular from a medical viewpoint, are those that impart to a virus its resistance regarding inhibitor agents that can block at least one mechanism that is involved in the viral activity, those that impart to a virus its replicative capacity, those that impart to a virus its 7 tropism to particular targets or else those that impart to a virus its aptitude to be neutralized by molecules, such as antibodies, chemokines or inhibitors.
This invention makes it possible to test several phenotypic characteristics that are distinct but complementary to HIV with a quick method that is based on the reconstruction of a recombinant virus starting from samples taken from infected patients and involving a unique cycle of viral replication. This invention is part of a process for decision-making and optimization of therapeutic strategy in HIV-infected patients for whom antiretroviral treatment has failed virologically or else in patients who have not undergone antiretroviral treatment. Only a complete knowledge of the different phenotypic characteristics of the virus can effectively help the clinician to make therapeutic decisions that are best suited to the particular situation of his patient.
Among the phenotypic characteristics of the HIV virus whose analysis exhibits a particular advantage from the medial viewpoint are found those that are linked to the expression of genes that can undergo at least one mutation, located in the GAG, ENV or POL regions of the viral genome, such as those listed below: C1 I Infectivity, Replicative Capacity and Virulence SThese phenotypic characteristics of the HIV virus can be linked to the function of all of the viral genome regions, in the case of parts that code for proteins or regions that occur in different mechanisms or stages of the viral replication cycle. In particular, it is C important to evaluate the effect that is produced by the mutations in genes that code for protease, the reverse transcriptase, the integrase or the envelope on viral replication and most particularly with viruses that have developed a resistance to antiviral agents.
CN Its analysis makes it possible to measure the replicative capacity of a virus, also called infectivity or "fitness." 1 Susceptibility/Resistance to Reverse Transcriptase Inhibitors This phenotypic characteristic of the HIV viruses is linked to the expression of a portion of the POL region that codes for the reverse transcriptase.
Its analysis allows the adjustment of antiretroviral treatments by nucleosidic analogs or non-nucleosidic reverse transcriptase inhibitors (NNRTI).
I Susceptibility/Resistance to Integrase Inhibitors.
This phenotypic characteristic of the HIV viruses is linked to the expression of a portion of the POL region that codes for the integrase.
Its analysis provides indications for adjusting antiretroviral treatments by integrase inhibitors.
IV Susceptibility/Resistance to Inhibitors of Virus Entry into the Target Cell.
SThis phenotypic characteristic of the HIV viruses is linked to the expression of the glycoprotein of the HIV envelope and in particular to the expression of the transmembrane subunit of said glycoprotein that is coded by a part of the ENV gene.
C
7, The analysis of this phenotypic characteristic allows the demonstration of the action of inhibitor agents that block the fusion of the viral membrane with the membrane of the target cell.
V Susceptibility/Resistance to Inhibitors that Target the Co-Receptors of the HIV Viruses.
This phenotypic characteristic is linked also to the expression of at least a portion of the ENV region of the HIV viruses that codes for polypeptides that participate in the connection with the co-receptors of the target cell. The envelope/co-receptor interaction allows the HIV virus to enter said target cell.
Its analysis makes it possible to measure the resistance of the HIV viruses to the action of inhibitors that block the co-receptors that are used by the HIV to carry out its entry into the target cell.
The inhibitor agents interfere with the co-receptor by inhibiting its interaction with the HIV envelope.
In particular, it is important to evaluate the effect of mutations in the ENV region that modify the interaction of certain regions of the envelope protein with the CXCR4 or receptors of the HIV target cells.
CI VI Tropism SThis phenotypic characteristic is also linked to the expression of at least a portion of the ENV region that codes for polypeptides of the envelope of HIV viruses that participate in the connection with one or more receptors of the target cell, in particular C with the CXCR4 or CCR5 co-receptors.
Its analysis makes it possible to measure in vivo the capacity of the HIV virus to Suse said receptors, in particular CXCR4 or CCR5, which are expressed in a different way C in various cellular types and makes it possible to know if the virus uses one or the other of the receptors, or both.
The indications provided by this analysis make it possible to deduce the viral behavior in some types of cells, natural targets of the HIV.
VII Virulence.
This phenotypic characteristic is also linked to the expression of all or part of the ENV region that codes for the envelope peptides of the HIV virus.
Its analysis makes it possible to evaluate the cytopathogenic power of an HIV virus.
VII Neutralizing Capacity.
This phenotypic characteristic is also linked to the expression of envelope proteins of the HIV viruses.
S Its analysis makes it possible to evaluate the susceptibility of viruses to the
O
N inhibiting action of antibodies or substances that are naturally present in the organism and Spresent in the serum or in other fluids.
The first tests for detecting, for example, the phenotypic characteristic of resistance of HIV viruses to antiviral treatments were carried out by using primary CN isolates and peripheral blood lymphocytes (PBL) stimulated by phytoagglutinin (PHA) according to a procedure that is laborious and difficult to reproduce. An innovative alternative to these tests, a recombinant virus test, named RVA below, was proposed by N Kellam and Larder in 1994.
This RVA analytical method measured the resistance of a recombinant virus carrying the reverse transcriptase isolated from the plasma of a virus-carrying patient by co-transfection of the sequences of the latter duly amplified by a polymerization chain reaction (PCR) with a virus clone obtained in a laboratory, which is deleted from its reverse transcriptase and is competent for replication in a variety of well-plotted cellular lines.
Several modifications of this method have now been described (Boucher, C.; Keulen, Bommel, Nijhuis, Jong, Jong, Schipper, P. and Back, K.
(1996) "HIV-1 Drug Susceptibility Determination by Using Recombinant Viruses Generated from Patient Sera Tested in a Cell-Killing Assay. Antimicrobial Agents and Chemotherapy" 40 2404-2409) (Shi, C. and Mellors, J. W. (1997) "A Recombinant Retroviral System for Rapid In Vivo Analysis of Human Immunodeficiency Virus Type 1 Susceptibility to Reverse Transcriptase Inhibitors." Antimicrob Agents Chemother 41 2781-5) (Hertogs, de Bethune, M. Miller, Ivens, Schel, Van Cauwenberge, Van Den Eynde, Van Gerwen, V.;
O
C1 Azijn, Van Houtte, Peeters, Staszewski, Conant, Bloor, Kemp, S.; Larder, B. and Pauwels, R. (1998) "A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates from Patients Treated C1 with Antiretroviral Drugs." Antimicrob Agents Chemother 42(2), 269-76.) (Hecht, F.
Grant, R. Petropoulos, C. Dillon, Chesney, M. Tian, Hellmann, N.
Bandrapalli, N. Digilio, Branson, B. and Kahn, J. 0. (1998) "Sexual C Transmission of an HIV-1 Variant Resistant to Multiple Reverse-Transcriptase and Protease Inhibitors." N Engl J Med 339 307-11) (Medina, D. Tung, P. Nelson, C. Sathya, Casareale, D. and Strair, R. K. (1998) "Characterization and Use of a Recombinant Retroviral System for the Analysis of Drug Resistant HIV." J Virol Methods 71 169-76).
Most of these recombinant systems, however, exhibit drawbacks because, as for the method that uses PBMC, the production of a reserve of infectious particles expressing a particular phenotypic characteristic that it is sought to detect and to measure requires an amplification of the virus by exponential growth of the lymphocytic cells. The virus is then subjected to genetic derivatives during its replication and can lose mutations that are essential for the expression of the desired phenotypic characteristic that thus modifies the reliability of the method.
Another drawback for indicating, for example, a phenotypic characteristic of resistance that is present in the methods for analysis of the prior art comes from the fact that the simultaneous presence of several mutations that can impart a resistance relative c to different retroviral inhibitors reduces the replicative capacity of the virus.
The inventors developed a new method for analysis of a phenotypic characteristic of the HIV viruses that requires only one replication cycle.
This method that requires only a single viral replication cycle is implemented by Sthe selection of culture conditions of the recombinant viruses that are obtained.
These culture conditions relate to the monitoring of the culture time, selected for preventing the viral replication beyond the first cycle; this culture time is between 12 7 hours to 72 hours, preferably 24 hours to 48 hours.
The culture conditions also relate to the selection of cells of the first cellular system; they are selected so that they are not permissive with regard to viral infection, for example such cells do not have the CD4 receptor that is necessary to the entry of the HIV virus into the cell. Examples of such cells are the HeLa or 293T cells.
Finally, these culture conditions also relate to the recombinant viruses that are constructed according to the method of the invention, which exhibit an envelope protein deficit. These viruses, once produced in the first cellular system, are actually incapable of reinfecting the cells of this first cellular system.
This analytical method is based on the construction of a recombinant virus (RAV) that is obtained by cotransfection and recombination homologous with: a) the ADN sequences that are obtained from an HIV to be analyzed and that can comprise mutations that can modify the desired phenotypic characteristic, whereby said sequences are extracted from a biological medium such as plasma, serum, saliva, sperm or other secretions, from a patient who is a
O
carrier of said virus, Sb) A first vector that exhibits a specific deletion of sequences that allow the replication of the HIV as well as a deletion of all or part of the sequence that imparts to the HIV the desired phenotypic characteristic and "1 c) A second vector, for example, a plasmid, that comprises the sequences that complete those that are necessary for the replication of said virus and that are absent from the first vector.
C7. The method developed by the inventors is quick; it requires about seven days to be carried out and can then be used for routine determinations such as the measurement of the susceptibility of HIV-infected patients to inhibitors of viral activity.
Thus, in Patent US 6 103 462, the inventors already described a first application of this analytical method, based on the formation of a particular recombinant virus to determine the susceptibility of an HIV virus to protease inhibitors.
The new analytical methods that are used within the scope of this HIV invention are based on the determination of HIV virus phenotypic characteristics that are associated with mutations that can be present at least in a gene that is selected from among the group that comprises the genes gag, pol, protease, reverse transcriptase, RNAse H, integrase, vif, vpr, tat, rev, vpu, env, nef, cis-active sequences, LTR, dimerization sequences, splicing-regulating sequences, and RRE with ad-hoc recombinant viruses.
The invention therefore relates to a method for analysis of a phenotypic characteristic of HIV viruses that are present in a biological sample from a patient, whereby said phenotypic characteristic results from one or more mutations of the viral C genome that can influence the viral infection, characterized in that it comprises: Sa) The extraction of nucleic acids that are contained in a biological sample, b) At least one amplification by PCR of a segment of the nucleic acids of stage each with a pair of primers that frame a nucleic acid sequence of the viral genome that can carry at least one mutation, c) The preparation of a vector that comprises the parts ofa genome of an HIV virus that are necessary for the viral replication except for the amplified C segment in stage and optionally with the exception of the gene that codes for the envelope protein, d) The transfection of a first cellular host with: The nucleic acids that are obtained in stage SThe vector that is prepared in stage Optionally a second vector that comprises a gene that codes for an envelope protein if the envelope gene is deleted from the vector that is prepared in stage (c) to obtain a chimerical virus by homologous recombination, e) The culture of said first cellular host under conditions that make it possible to produce viral particles during a single replication cycle, f) The infection by the viral particles that are obtained in stage from at least a second cellular host that can be infected by an HIV virus or an HIVpseudotype virus and that optionally comprises a marker gene that can be activated only following viral infection, and g) The detection and/or the quantification of the marker that is expressed in stage Cl so as to demonstrate at least one phenotypic characteristic of the HIV Sviruses that are present in the biological sample.
SMore particularly, the amplification by PCR of stage is carried out with a pair of primers that frame a nucleic acid sequence that comprises all or part of a viral genome CI region that is selected from among: gag, pol, protease, reverse transcriptase, RNAse H, integrase, vif, vpr, tat, rev, vpu, env, nef, cis-active sequences, LTR, dimerization sequences, splicing-regulating sequences or the Rev response element (RRE).
CI According to a particular embodiment of the analytical method of the invention, the amplification by PCR of stage is carried out with a pair of primers that frame a nucleic acid sequence that codes for a portion of the gag protein of the human immunodeficiency virus and a nucleic acid sequence that codes for the protease that can carry at least one mutation in the gene that codes for the protease and in that the vector of stage is constructed from a genome of an HIV virus where all or part of the gene that codes for the protease is deleted.
Advantageously, the amplification of stage according to the analytical method of the invention of a nucleic acid sequence that can carry at least one mutation in the gene that codes for the protease is made with a pair of primers having a size of between 10 and oligonucleotides, comprising the sequences Fit A TCA CCT AGA ACT TTA AAT GC (SEQ ID No 1) and Pro A- GGC AAA TAC TGG AGT ATT GTA TG3' (SEQ ID No or constituted of fragments of the latter or else sequences analogous to the latter that carry mutations of one or more nucleotides that do not significantly modify their capacity to hybridize the region of the gene of the protease that carries the mutation or mutations, followed by a second amplification with a pair of 0 Cr primers having a size of between 10 and 50 oligonucleotides, comprising the sequences: SFit B AGA ACT TTA AAT GCA TGG GT (SEQ ID No 3) and Pro B- GGA GTA TTG TAT GGA TTT TCA GG (SEQ ID No or constituted of fragments of the latter, or else sequences analogous to the latter that carry mutations of C one or more nucleotides that do not significantly modify their capacity to hybridize the region of the gene of the protease that carries the mutation or mutations.
Quite preferably, the amplification of stage according to the analytical method C of the invention of a nucleic acid sequence that can carry at least one mutation in the gene that codes for the protease is made with a pair of primers: Fit A TCA CCT AGA ACT TTA AAT GC (SEQ ID No 1) and Pro GGC AAA TAC TGG AGT ATT GTA TG3' 3) (SEQ ID No 2), followed by a second amplification with a pair of primers Fit B AGA ACT TTA AAT GCA TGG GT (SEQ ID No and Pro GGA GTA TTG TAT GGA TTT TCA GG (SEQ ID No 4), to obtain an ADN segment of 1488 base pairs that extend between residues 1237 and 2725 inclusive, and the vector of stage is a retroviral vector that is deleted from the region of the pol reading frame that codes for the HIV-1 protease that extends from residues 1505 to 2565 inclusive, deleted from the envelope region and comprising a single restriction site Mlul.
According to a second particular embodiment of the analytical method of the invention, the amplification by PCR of stage of the analytical method according to the invention is carried out with a pair of primers that frame a nucleic acid sequence that can Scarry at least one mutation in the gene that codes for the reverse transcriptase, and the
O
C transfection of stage is carried out with a first vector that is constructed from a Sgenome of an HIV virus where all or part of the gene that codes for the reverse transcriptase is deleted.
Advantageously, the amplification of stage according to the analytical method CN of the invention, with a pair of primers that frame a nucleic acid sequence that can carry at least one mutation in the gene that codes for the reverse transcriptase, is made with a pair of primers having a size of between 10 and 50 oligonucleotides, comprising ri sequences MJ3 AGT AGG ACC TAC ACC TGT CA (SEQ ID No 5) and RT- EXT TTC CCA ATG CAT ATT GTG AG (SEQ ID No or constituted of fragments of the latter, or else sequences analogous to the latter that carry mutations of one or more nucleotides that do not significantly modify their capacity to hybridize the region of the gene of the transcriptase that carries at least one mutation, followed by a second amplification stage with a pair of primers comprising the sequences A35 TTG GTT GCA TAA ATT TTC CCA TTA GTC CTA TT (SEQ ID No 7) and RT- IN TTC CCA ATG CAT ATT GTG AG (SEQ ID No 8) or constituted of fragments of the latter, or else sequences that are analogous to the latter that carry mutations of one or more nucleotides that do not significantly modify their capacity to hybridize the region of the gene of the reverse transcriptase that carries at least one mutation.
Quite preferably, the amplification of stage according to the analytical method of the invention, with a pair of primers that frame a nucleic acid sequence that can carry at least one mutation in the gene that codes for the reverse transcriptase is made with a
O
CI pair of primers: MJ3 AGT AGG ACC TAC ACC TGT CA (SEQ ID No: 5) and RT-EXT TTC CCA ATG CAT ATT GTG AG (SEQ ID No 6), followed by a second amplification stage with a pair of primers: CI A35 TTG GTT GCA TAA ATT TTC CCA TTA GTC CTA TT (SEQ ID No 7) and
I
RT-IN TTC CCA ATG CAT ATT GTG AG (SEQ ID No 8) CI to obtain an ADN segment of 1530 base pairs that extend beyond codon 93 of the region that codes for the protease and beyond codon 503 of the region that codes for the polymerase (POL), and the vector of stage is a retroviral vector that is deleted from the region of the pol reading frame that codes for the HIV-1 reverse transcriptase that extends from residues 2618 to 2872 inclusive and comprises a unique restriction site Mlul.
According to a third embodiment, the invention also has as its object an analytical method according to which the amplification of stage is carried out with a pair of primers that frame a nucleic acid sequence that codes for a portion of the gag protein, for the protease and for a portion of the reverse transcriptase of the human immunodeficiency virus that can carry at least one mutation in the nucleic acid sequence that codes for the gag protein or for the protease or for the reverse transcriptase.
Quite preferably, the amplification of stage with a pair of primers that frame a nucleic acid sequence that codes for a portion of the gag protein, for the protease and for a portion of the reverse transcriptase of the human immunodeficiency virus that can carry 0 at least one mutation in the nucleic acid sequence that codes for the gag protein or for the C protease or for the reverse transcriptase is carried out with the pair of primers: gag+1 AGGGGCAAATGGTACATCA (SEQ ID No 31) and SRT-EX (SEQ ID No 6), followed by a second amplification stage with a pair of primers Fit B+ (SEQ ID No 1) and RT-IN (SEQ ID No 8) to obtain an ADN segment of 2825 base pairs that extend between residues 1237 C and 4062, and the transfection of stage is carried out with a retroviral vector that is deleted from a portion of the gag gene and regions within the pol reading frame that codes for the protease and a portion of the HIV-1 reverse transcriptase that extends from residues 1507 to 3870 inclusive, deleted in the envelope region and comprising a unique restriction site NruI.
Advantageously, the virus that results from the transfection that is mentioned above can be used to determine the infective or replicative capacity of the virus that has mutations in the reverse transcriptase and/or protease. The quantification of the viral particles according to this last analytical method is accomplished by the measurement of the antigen p24. It should be pointed out that a similar analytical method can in no case be carried out by using a vector that is deleted simply from the sequence of the reverse transcriptase since these non-viable recombinant viruses can also produce antigen p24.
By constructing a recombinant virus that has an additional deletion of the region corresponding to the protease, only the correctly recombined viruses produce the antigen p2 4 and thus make possible a certain and reliable measurement of the viral particles that 0 C, are produced.
SThe invention also relates to an analytical method for determining the Ssusceptibility of an HIV virus to an inhibiter compound of the reverse transcriptase, consisting in adding or not adding said inhibitor compound of the reverse transcriptase, C, optionally at different concentrations, to the second cellular host, prior to the infection of the latter by viral particles that are obtained in stage and comprising in stage the comparison of the expression of the marker gene with and without an inhibitor compound ,I of the reverse transcriptase.
According to a third particular implementation of the analytical method of the invention, the amplification by PCR of stage is carried out with a pair of primers that frame a nucleic acid sequence that can carry at least one mutation in the gene that codes for the integrase, and the vector of stage is a retroviral vector that is deleted from all or part of the gene that codes for the integrase.
Advantageously, the amplification of stage according to the analytical method of the invention with a pair of primers that frame a nucleic acid sequence that can carry at least one mutation in the gene that codes for the integrase is made with the pair of primers having a size of between 10 and 50 oligonucleotides, comprising the sequences INT B+ 5' GTTACTAATAGAGGAAGACAAA3' (SEQ ID No: 9) and INT TTTTGGTGTTATTAATGCT3' (SEQ ID No: 10), or else sequences analogous to the latter that carry mutations of one or more nucleotides that do not significantly modify their capacity to hybridize the region of the gene of the integrase carrying at least one mutation, followed by a second amplification stage, with the pair of primers: INT V+ CACCCTAACTGACACAACAA3' (SEQ ID No 11) and INT V- Cl AAGGCCTTTCTTATAGCAGA3' (SEQ ID No 12), or else sequences that are Sanalogous to the latter and that carry mutations of one or more nucleotides that do not significantly modify their capacity to hybridize the region of the gene of the integrase that carries at least one mutation.
l Quite preferably, the amplification of stage according to the analytical method of the invention with a pair of primers that frame a nucleic acid sequence that can carry at least one mutation in the gene that codes for the integrase is made with the pair of C, primers: INT B+ GTTACTAATAGAGGAAGACAAA3' (SEQ ID No: 9) and INT B- 5' TTTTGGTGTTATTAATGCT3' (SEQ ID No: followed by a second amplification stage, with the pair of primers: INT V+ 5' CACCCTAACTGACACAACAA3' (SEQ ID No. 11), and INT V- 5' AAGGCCTTTCTTATAGCAGA3' (SEQ ID No. 12), to obtain an ADN fragment of 1460 base pairs that extend from residues 3950 to 5410 inclusive, and the vector of stage is a retroviral vector that is deleted from the entire region of the pol reading frame that codes for the HIV-1 integrase that extends from residues 4228 to 5093 inclusive and from the region that codes for the viral envelope between positions 6343 and 7611 inclusive.
The invention also relates to an analytical method for determining the susceptibility of an HIV virus to an inhibitor compound of the integrase, consisting in adding or not adding said inhibitor compound of the integrase, optionally at different concentrations, during stage before stage and comprising in stage the comparison of the expression of the marker gene with and without an inhibitor compound
O
CN of the integrase.
SAccording to a fourth particular implementation of the analytical method of the invention, the amplification by PCR of stage is carried out with a pair of primers that frame a nucleic acid sequence that can carry at least one mutation in the gene that codes N for the envelope protein, and the vector of stage is a retroviral vector that is constructed from a genome of an HIV virus where all or part of the gene that codes for the envelope protein is deleted.
CN The vector of stage is preferably a retroviral vector that is deleted from the entire region that codes for the extracellular portion of sub-unit gp41 of the HIV-1 envelope that extends from residues 7745 to 8263 inclusive, from the region of the HIV-1 genome that constitutes the Rev response element (RRE).
Advantageously, the amplification of stage with a pair of primers that frame a nucleic acid sequence that can carry at least one mutation in the gene that codes for the envelope protein is made with a pair of primers having a size of between 10 and oligonucleotides, comprising either sequences FIN-A TCAAATATTACAGGGCTGCT3' (SEQ ID No: 13) and FIN-B TAGCTGAAGAGGCACAGG3' (SEQ ID No: 14) or sequences FuA: AAGCAATGTATGCCCCTCCCAT3' (SEQ ID No: 23) and FuB: GGTGGTAGCTGAAGAGGCACAGG3' (SEQ ID No: 24) or constituted of fragments of the latter or else by sequences that are analogous to the latter carrying mutations of one or more nucleotides that do not significantly modify their capacity to hybridize the region of the gene of the envelope that carries at least one mutation followed by a second amplification stage, carried out with a pair of primers having a size of between 10 and c1 oligonucleotides, comprising either the sequences: FIN-C: Q CTATTAACAAGAGATGGTGG3' (SEQ ID No: 15) and FIN-D: TCCACCTTCTTCTTCGATT3' (SEQ ID No: 16), or sequences FuC': ATATGAGGGACAATTGGAGAAGTGA3' (SEQ ID No: 25), used in combination C with a mixture of the following two sequences: FuDl TCTGTCTCTCTCTCCACCTTCTTCTT3' (SEQ ID No: 26) and FuD2 TCTGTCTTGCTCTCCACCTTCTTCTT3' (SEQ ID No: 27) or constituted of fragments of the latter or else by sequences that are analogous to the latter that carry mutations of one or more nucleotides that do not significantly modify their capacity to hybridize the region of the gene of the envelope that carries at least one mutation.
Quite preferably, the amplification of stage with a pair of primers that frame a nucleic acid sequence that can carry at least one mutation in the gene that codes for the envelope protein is made with a pair of primers: FIN-A 5' TCAAATATTACAGGGCTGCT3' (SEQ ID No: 13) and FIN-B 5' TAGCTGAAGAGGCACAGG3' (SEQ ID No: 14) followed by a second amplification stage that is carried out with the pair of primers: FIN-C: 5' CTATTAACAAGAGATGGTGG3' (SEQ ID No: 15) and FIN-D 5' TCCACCTTCTTCTTCGATT3' (SEQ ID No: 16), to obtain an ADN segment of 965 base pairs that extend from residues 7553 to 8517 inclusive and the vector of stage is a retroviral vector that is deleted from the entire region that codes for the extracellular portion of sub-unit gp41 of the HIV-1 envelope that extends from residues 7745 to 8263 inclusive and comprises a unique C restriction site Mull.
Quite preferably, the analytical method according to the invention makes possible the amplification of sequences of the envelope region of the HIV virus regardless of their sub-type and in particular viruses of sub-types A, B, C, D and by using, for the N amplification stage with a pair of primers that frame a nucleic acid sequence that can carry at least one mutation in the gene that codes for the envelope protein is made with a pair of primers: <C FuA 5' AAGCAATGTATGCCCCTCCCAT3' (SEQ ID No: 23) and FuB 5' GGTGGTAGCTGAAGAGGCACAGG3' (SEQ ID No: 24) followed by a second amplification stage that is carried out with the primer: FuC 5' ATATGAGGGACAATTGGAGAAGTGA3' (SEQ ID No: and a mixture of the following primers: FuDI 5' TCTGTCTCTCTCTCCACCTTCTTCTT3' (SEQ ID No: 26) FuD2: 5' TCTGTCTTGCTCTCCACCTTCTTCTT3' (SEQ ID No: 27), whereby said mixture is preferably carried out in a ratio of between (10% and (90% 10%) and quite preferably between (60% 40%) and (40% to obtain an ADN segment of 805 base pairs that extend from residues 7635 to 8440 inclusive, and the vector of stage is a retroviral vector that is deleted from the entire region that codes for the extracellular portion of sub-unit gp41 of the HIV-1 envelope that extends from residues 7745 to 8263 inclusive and comprises a unique restriction site Mu1.
Advantageously, the amplification of stage with a pair of primers that frame a
O
C nucleic acid sequence that can carry at least one mutation in the gene that codes for the envelope protein is made with a pair of primers having a size of between 10 and Soligonucleotides, comprising the sequences: NEU-A TAGAAAGAGCAGAAGACAGTGGCAATG3' (SEQ ID No: 17) and FIN-B: TAGCTGAAGAGGCACAGG3' (SEQ ID No: 14) or FuB GGTGGTAGCTGAAGAGGCACAGG3' (SEQ ID No: 24) or constituted of fragments of the latter, or else by sequences that are analogous to the latter that carry mutations of C one or more nucleotides that do not significantly modify their capacity to hybridize the region of the gene of the envelope that carries at least one mutation, followed by a second amplification stage, with the pair of primers having a size of between 10 and oligonucleotides, comprising the sequences: NEU-C GTGGGTCACAGTCTATTATGGGG3' (SEQ ID No: 18) and FIN-D TCCACCTTCTTCTTCGATT3' (SEQ ID No: 16) or a mixture of the following sequences: FuDI 5' TCTGTCTCTCTCTCCACCTTCTTCTT3' (SEQ ID No: 26) and FuD2 5' TCTGTCTTGCTCTCCACCTTCTTCTT3' (SEQ ID No: 27), or constituted of fragments of the latter, or else by sequences that are analogous to the latter carrying mutations of one or more nucleotides that do not significantly modify their capacity to hybridize the region of the gene of the envelope that carries at least one mutation.
Quite preferably, the amplification of stage with a pair of primers that frame a nucleic acid sequence that can carry at least one mutation in the gene that codes for the envelope protein is made with a pair of primers: NEU-A: 5' TAGAAAGAGCAGAAGACAGTGGCAATG3' (SEQ ID No: 17) ,1 and FIN-B 5' TAGCTGAAGAGGCACAGG3' (SEQ ID No: 14), followed by a second amplification stage, with the pair of primers: NEU-C 5' GTGGGTCACAGTCTATTATGGGG3' (SEQ ID No: 18) and cI FIN-D 5' TCCACCTTCTTCTTCGATT3' (SEQ ID No: 16), to obtain an ADN fragment of between 2106 and 2320 base pairs that extend from residues 6197-6222 up to residues 6197-6222 inclusive and the vector of stage is a CI retroviral vector that is deleted from the entire region that codes for the majority of subunit gpl20 and the extracellular portion ofgp41 of the HIV-1 envelope that extends from residues 6480 to 8263 inclusive and comprises a unique restriction site Mul 1.
Quite preferably, the amplification of stage with a pair of primers that frame a nucleic acid sequence that can carry at least one mutation in the gene that codes for the envelope protein is made with a pair of primers: NEU-A 5' TAGAAAGAGCAGAAGACAGTGGCAATG3' (SEQ ID No: 17) and FuB 5' GGTGGTAGCTGAAGAGGCACAGG3' (SEQ ID No: 24), followed by a second amplification stage, with the primers: NEU-C 5' GTGGGTCACAGTCTATTATGGGG3' (SEQ ID No: 18) and a mixture of the following primers FuDI 5' TCTGTCTCTCTCTCCACCTTCTTCTT3' (SEQ ID No: 26) and FuD2 5' TCTGTCTTGCTCTCCACCTTCTTCTT3' (SEQ ID No: 27), whereby said mixture is preferably carried out in a ratio that is between (10% 0 CN 90%) and (90% 10%) and quite preferably between (60% 40%) and (40% Sto obtain an ADN fragment of 2118 base pairs that extend from residues 6322 to S8440 inclusive, and the vector of stage is a retroviral vector that is deleted from the entire region that codes for the majority of sub-unit gp 120 and the extracellular portion of C1 the gp41 of the HIV-1 envelope that extends from residues 6480 to 8263 inclusive and comprises a unique restriction site Mul l.
Advantageously, the amplification of stage with a pair of primers that frame a C nucleic acid sequence that can carry at least one mutation in the gene that codes for the envelope protein is made with a pair of primers having a size of between 10 and nucleotides, comprising the sequences: E 00 5' TAGAAAGAGCAGAAGACAG- TCGCAATGA3' (SEQ ID No: 19) and ES8B 5' CACTTCTCCAATTGTCCCTCA3' (SEQ ID No: 20), or constituted of fragments of the latter, or else by sequences that are analogous to the latter that carry mutations of one or more nucleotides that do not significantly modify their capacity to hybridize the region of the gene of the envelope that carries at least one mutation, followed by a second amplification stage, with a pair of primers having a size of between 10 and 50 oligonucleotides comprising the sequences: 5' GGGCCACACATGCCTGTGTACCCACAG3' (SEQ ID No: 21) and E 15 AGAAAAATTCCCCTCCACAATTAA3' (SEQ ID No: 22) or else by sequences that are analogous to the latter carrying mutations of one or more nucleotides that do not significantly modify their capacity to hybridize the region of the gene of the protease that carries at least one mutation.
Quite preferably, the amplification of stage with a pair of primers that frame a 0 C1 nucleic acid sequence that can carry at least one mutation in the gene that codes for the Senvelope protein is made with a pair of primers: EOO 5' TAGAAAGAGCAGAAGACAGTGGCAATGA3' (SEQ ID No: 19) and Ci ES8B 5' CACTTCTCCAATTGTCCCTCA3' (SEQ ID No: followed by a second amplification stage with the pair of primers: E20 5' GGGCCACACATGCCTGTGTACCCACAC3' (SEQ ID No: 21) and C E1l15 5' AGAAAAATTCCCCTCCACAATTAA3' (SEQ ID No: 22), to obtain an ADN segment of 938 base pairs that extend from residues 6426 to 7364 inclusive, and the vector of stage is a retroviral vector that is deleted from the region, coding for the domains that extend from loop VI to loop V3 of the HIVenvelope that extends from 6617 to 7250 inclusive and comprises a unique restriction site NheI.
The invention also relates to an analytical method for determining the susceptibility of an HIV virus to a fusion-inhibitor compound that targets the gp41 protein of HIV-1, consisting in carrying out the amplification of stage either with the pair of primers SEQ ID No: 13 and SEQ ID No: 14 followed by a second amplification with the pair of primers SEQ ID No: 15 and SEQ ID No: 16, or with the pair of primers SEQ ID No: 17 and SEQ ID No: 18, followed by a second amplification with the pair of primers SEQ ID No: 18 and SEQ ID No: 16, said fusion-inhibitor compound, optionally at different concentrations, to be added or not added during the cultivation of the cellular host that is obtained in stage before stage and comprising in stage the comparison of the expression of the marker gene with and without a fusion-inhibitor C, compound targeting the gp41 of H1V-1.
SThe invention also relates to an analytical method for determining the susceptibility of an HIV virus to a compound that inhibits the entry of said HIV virus into a target cell, consisting in carrying out the amplification of stage with the pair of Sprimers SEQ ID No: 17 and SEQ ID No: 18 followed by a second amplification with the pair of primers SEQ ID No: 18 and SEQ ID No: 16, said compound that inhibits entry, optionally at different concentrations, to be added or not added to the cellular host that is obtained in stage before the infection of stage and comprising in stage the comparison to the expression of the marker gene with and without a compound that inhibits entry.
The invention also relates to an analytical method for determining the susceptibility of an HIV virus to the inhibiting action of antibodies, consisting in carrying out the amplification of stage with the pair of primers SEQ ID No: 17 and SEQ ID No: 18, followed by a second amplification with the pair of primers SEQ ID No: 18 and SEQ ID No: 16, said antibodies, optionally at different concentrations and comprising in stage the comparison of the expression of the marker gene with and without antibodies, to be added or not added during cultivation stage The invention also relates to an analytical method for determining the tropism of an HIV virus for a cellular receptor, consisting in carrying out the amplification of stage with the pair of primers SEQ ID No: 17 and SEQ ID No: 18, followed by a second amplification with the pair of primers SEQ ID No: 18 and SEQ ID No: 16, to carry out the infection of stage with the viral particles that are obtained in stage on two separate cellular hosts and comprising in stage the comparison of the expression of the marker gene by each of the two separate cellular hosts.
SAdvantageously, the cellular hosts that are used for the infection of stage (f) according to the analytical method of the invention are selected from among cellular hosts that express the CCR5 receptor or the CXCR4 receptor.
,I The invention also relates to an analytical method for determining the susceptibility of an HIV virus to an inhibitor compound that targets the co-receptors of HIV-1, consisting in carrying out the amplification of stage with the pair of primers SEQ ID No: 17 and SEQ ID No: 18, followed by a second amplification with the pair of primers SEQ ID NO: 18 and SEQ ID No: 16, said inhibitor compound that targets the coreceptors of HIV-1, optionally at different concentrations, to be added or not added during cultivation stage whereby the infection of stage is carried out on two separate cellular hosts and comprises in stage the comparison of the expression of the marker gene by each of the two separate cellular hosts.
The invention also relates to an analytical method for determining the tropism of an HIV virus for a cellular receptacle, consisting in carrying out the amplification of stage with the pair of primers SEQ ID No: 19 and SEQ ID No: 20, followed by a second amplification with the pair of primers SEQ ID No: 21 and SEQ ID No: 22, to infect in stage two separate cellular hosts with the viral particles that are obtained in stage and that comprise in stage the comparison of the expression of the marker gene by each of the two separate cellular hosts.
The invention also relates to an analytical method for determining the susceptibility of an HIV virus to an inhibitor compound that targets the co-receptors of HIV-1, consisting in carrying out the amplification of stage with the pair of primers SEQ ID No: 19 and SEQ ID No: 20, followed by a second amplification with the pair of Sprimers SEQ ID No: 21 and SEQ ID No: 22, said inhibitor compound that targets the coreceptors of HIV-1, optionally at different concentrations, to be added or not added during the cultivation of stage to carry out the infection of stage with the viral particles that are obtained in stage on two separate cellular hosts and to compare in stage the expression of the marker gene by each of the two separate cellular hosts.
The invention also relates to an analytical method for determining the infectivity or the replicative capacity of an HIv virus consisting in comparing to stage the expression of the marker gene by the second cellular host that is infected with the viral particles that are obtained by applying stages to to a biological sample of a patient, and the expression of the marker gene by the same second cellular host infected with reference viral particles that are obtained by applying stages to to a sample that contains a reference virus.
Advantageously, the reference viral particles that are obtained from a reference virus are viral particles that are obtained by the application of stages to to a biological sample of the same patient at a stage prior to the therapeutic treatment or before the latter.
The invention also relates to an analytical method for determining the virulence of an HIV virus that consists in carrying out the amplification of stage either with the pair of primers SEQ ID No: 13 and SEQ ID No: 14, followed by a second amplification with the pair of primers SEQ ID No: 15 and SEQ ID No: 16, or with the pair of primers SEQ ID No: 17 and SEQ ID No: 18, followed by a second amplification with the pair of primers SEQ ID No: 18 and SEQ ID No: 16, and to measure, during the infection of stage
O
the cytopathogenic effect that is produced on the second cellular host.
O Advantageously, the cytopathogenic effect produced during the infection of stage on the second cellular host is measured by means of cytotoxicity techniques such as the measurement of the induction of syncytia, the induction of apoptosis or by flow cytometry.
The invention also relates to an analytical method for determining the susceptibility of an HIV virus to hydroxyurea, consisting in adding or not adding C hydroxyurea, optionally at different concentrations, either during cultivation stage or to the second cellular host and in carrying out in stage the comparison of the expression of the marker gene with and without hydroxyurea.
According to the method of the invention, the duration of cultivation stage is preferably between 12 and 72 hours; quite preferably it is between 24 and 48 hours.
The invention also has as its object a kit for the implementation of an analytical method of a phenotypic characteristic of the HIV viruses that are present in a biological sample of a patient, characterized in that it comprises: i. a pair of primers that frame a nucleic acid sequence of the viral genome that can carry at least one mutation, ii. a vector that comprises the parts of a genome of an HIV virus that are necessary to the viral replication except for the segment amplified with the primers that are defined in and the gene that codes for the envelope protein, iii. a second vector that comprises a gene that codes for an envelope protein, Siv. a first cellular host that can be infected by an HIV virus, 0 C v. a second cellular host that can be infected by an HIV virus and that Scomprises a marker gene that can be activated only following viral infection, vi. the products and reagents necessary for carrying out the amplification by
SPCR,
vii. the products and reagents that make it possible to detect the expressed marker.
C Advantageously, the kit according to the invention comprises: i. the sequence primer pairs: SEQ ID No: 1 and SEQ ID No: 2 SEQ ID No: 3 and SEQ ID No: 4 ii. a retroviral vector that is deleted from the region of the pol reading frame that codes for the HIV-1 protease that extends from residues 1505 to 2565 inclusive, deleted from the envelope region and comprising a unique restriction site Mlul, iii. a pseudotype virus with a gene that codes for an envelope protein, iv. a first cellular host that can be infected by an HIV virus, v. a second cellular host that can be infected by an HIV virus and that comprises a marker gene that can be activated only following viral infection, vi. the products and reagents that are necessary for carrying out the amplification by PCR, vii. the products and reagents that make it possible to detect the expressed
O
marker.
SAdvantageously, the kit according to the invention comprises: i. the sequence primer pairs: SEQ ID No: 5 and SEQ ID No: 7 SEQ ID No: 6 and SEQ ID No: 8 ii. a retroviral vector that is deleted from the region of the pol reading frame that codes for the HIV-1 reverse transcriptase that extends from residues S2618 to 2872 inclusive and comprises a unique restriction site M1ul, iii. a virus that is pseudotyped by a gene that codes for an envelope protein, iv. a first cellular host that can be infected by an HIV virus, v. a second cellular host that can be infected by an HIV virus and that comprises a marker gene that can be activated only following viral infection, vi. the products and reagents that are necessary for carrying out the amplification by PCR, vii. the products and reagents that make it possible to detect the expressed marker.
Advantageously, the kit according to the invention comprises: i. the sequence primer pairs: SEQ ID No: 9 and SEQ ID No: SEQ ID No: 11 and SEQ ID No: 12 ii. a retroviral vector that is deleted from the entire region of the pol reading
O
frame that codes for the HIV-1 integrase that extends from residues 4228 Sto 5093 inclusive and the region that codes for the viral envelope between positions 6343 and 7611 inclusive, iii. a virus that is pseudotyped by a gene that codes for an envelope protein, iv. a first cellular host that can be infected by an HIV virus, v. a second cellular host that can be infected by an HIV virus and that comprises a marker gene that can be activated only following viral Cinfection, vi. the products and reagents that are necessary for carrying out the amplification by PCR, vii. the products and reagents that make it possible to detect the expressed marker.
Advantageously, the kit according to the invention comprises: i. the sequence primer pairs: SEQIDNo: 13 and SEQ ID No: 14 SEQIDNo: 15 and SEQ ID No: 16 ii. a retroviral vector that is deleted from the entire region that codes for the extracellular portion of sub-unit gp41 of the HIV-1 envelope that extends from residues 7745 to 8263 inclusive and comprises a unique restriction site Mu 11, iv. a first cellular host that can be infected by an HIV virus, Sv. a second cellular host that can be infected by an HIV virus and that 0 comprises a marker gene that can be activated only following viral Sinfection, vi. the products and reagents that are necessary for carrying out the amplification by PCR, C vii. the products and reagents that make it possible to detect the expressed marker.
Advantageously, the kit according to the invention comprises: C i. the sequence primer pairs: SEQIDNo: 17 and SEQ ID No: 14 SEQ ID No: 18 and SEQ ID No: 16 ii. a retroviral vector that is deleted from the entire region that codes for the majority of sub-unit gpl20 and the extracellular portion of the gp41 of the HIV-1 envelope that extends from residues 6480 to 8263 inclusive and comprises a unique restriction site Mul l, iv. a first cellular host that can be infected by an HIV virus, v. a second cellular host that can be infected by an HIV virus and that comprises a marker gene that can be activated only by viral particles, vi. the products and reagents that are necessary for carrying out the amplification by PCR, vii. the products and reagents that make it possible to detect the expressed marker.
Advantageously, the kit according to the invention comprises: i. the sequence primer pairs: 0 C, SEQ ID No: 19 and SEQ ID No: SEQ ID No: 21 and SEQ ID No: 22 ii. a retroviral vector that is deleted from the region, coding for the domains that extend from loop VI to loop V3 of the HIV-1 envelope that extends C from 6617 to 7250 inclusive and comprises a unique restriction site NheI, iv. a first cellular host that can be infected by an HIV virus, v. a second cellular host that can be infected by an HIV virus and that comprises a marker gene that can be activated only following viral infection, vi. the products and reagents that are necessary for carrying out the amplification by PCR, vii. the products and reagents that make it possible to detect the expressed marker.
Advantageously, the kit according to the invention comprises: i. the sequence primer pairs: SEQ ID No: 23 and SEQ ID No: 24 SEQ ID No: 25 and SEQ ID No: 26 with SEQ ID No: 27 ii. a retroviral vector that is deleted from the entire region that codes for the extracellular portion of sub-unit gp41 of the HIV- envelope that extends from residues 7745 to 8263 inclusive and comprises a unique restriction site Mull, iv. a first cellular host that can be infected by an HIV virus, v. a second cellular host that can be infected by an HIV virus and that 0 C comprises a marker gene that can be activated only following viral d infection, vi. the products and reagents that are necessary for carrying out the amplification by PCR, Ci vii. the products and reagents that make it possible to detect the expressed marker.
Advantageously, the kit according to the invention comprises: Si. the sequence primer pairs: SEQ ID No: 17 and SEQ ID No: 24 SEQ ID No: 18 and SEQ ID No: 26 and SEQ ID No: 27 ii. a retroviral vector that is deleted from the entire region that codes for the majority of sub-unit gpl20 and the extracellular portion of the gp41 of the HIV-1 envelope that extends from residues 6480 to 8263 inclusive and comprises a unique restriction site Mul 1, iv. a first cellular host that can be infected by an HIV virus, v. a second cellular host that can be infected by an HIV virus and that comprises a marker gene that can be activated only by viral particles, vi. the products and reagents that are necessary for carrying out the amplification by PCR, vii. the products and reagents that make it possible to detect the expressed marker.
Other advantages and characteristics of the invention are illustrated in the following examples that refer to the following figures:
O
Figure 1 diagrammatically shows the plasmid pSRT. The region that codes for Sthe reverse transcriptase of pNL4-3xcenv is deleted by means of digestion by Ball- SnaBI. The linearization of the resulting pSRT is accomplished by using Nru I Figure 2 illustrates the curves of the dose response effects obtained for two patients versus AZT and 3TC, before and after treatment with inhibitors of reverse transcriptase.
The details of the treatment, the sampling relative to the time, and the genotypes are found in the headings of the figures.
The curves show the inhibition of the infection by a recombinant virus of P4 cells treated either with ziodvudine (AZT, sample groups A and C) or lamivudine (3TC, sample groups B and according to the technique that is described later, in the Equipment and Methods paragraph. For patient I, the samples were tested at 0 9 and 18 months after treatment, and for patient 2 at 0 and 27 months after treatment.
Figure 3 is a diagram of the first stages (a and b) of a particular implementation of the method of the invention. The diagram illustrates the stages of extraction and amplification of the reverse transcriptase sequences that are extracted from the plasma of a patient by RT PCR of the method of the invention as well as the diagrams of plasmid pRVA/RT constructions used later in stage Figure 4 is a diagram of stages to of a particular implementation of the method of the invention. This diagram illustrates stage of co-transfection in HeLa/293T cells of the amplified nucleic acids of stage of a first plasmid
I
p43xcsnAenv RT constructed from a genome of an HIV virus, not comprising a nucleic
O
acid segment that corresponds to all or part of the amplified nucleic acid sequence in Sstage nor a fragment of the nucleic acid sequence that codes for the envelope protein and a second pVSV-G plasmid that comprises the sequence that codes for the envelope protein; whereby cultivation stage makes it possible to produce viral particles, stage C, for transfection of viral particles that are obtained in stage into P4 cells, previously incubated with or without the presence of serial dilutions of different inhibitors of reverse transcriptase, whereby said P4 indicating cells comprise a system for expression of the gene that codes for the beta-galactosidase enzyme that can be activated only by the activation sequences tat that are expressed by the recombinant virus, and stage for detection and/or quantification of the beta-galactosidase by means of substrate CPRG.
Figure 5 illustrates the results of the phenotypic analysis obtained in the presence of the T20 fusion inhibitor for viruses that are present in the plasmas of patients (P1, P2 and P3) and reference viral prototypes (N L 43 and the resistant clone DIM).
Figure 6 illustrates the results of the measurement of the replicative capacity of viruses LI, L2 and L3 that are extracted from different samples.
I. Equipment and Methods I.1 Amplification by Chain Polymerization Reaction (PCR).
The RNA is isolated from the plasma of the patients by means of a Roche Amplicorยฎ tool kit (Roche Diagnostics, 38242 Meylan Cedex, France), and the genes of interest are isolated by means of a reverse transcriptase and a subsequent PCR reaction.
The amplification of the region that codes for the reverse transcriptase (RT) is
O
C carried out by means of external primers MJ3 AGT AGG ACC TAC ACC TGT CA S3') (sequence SEQ ID NO: 5, attached) and RT-EXT TTC CCA ATG CAT ATT GTG AG (sequence SEQ ID NO: 6, attached) and internal primers A35 TTG GTT GCA TAA ATT TTC CCA TTA GTC CTA TT (sequence SEQ ID No: 7, (C attached) and RT-IN TTC CCA ATG CAT ATT GTG AG (sequence SEQ ID No: 8, attached) with an initial cycle at 50 0 C (30 minutes) and at 94 0 C (2 minutes), followed by 40 cycles at 94 0 C (30 seconds), 55ยฐC (30 seconds) and 68 0 C (90 seconds), and a final C"1 extension stage at 98 0 C for 10 minutes. This amplifies a product of 1530 pb that extends beyond codon 93 of the region that codes the protease and beyond codon 503 of the region that codes the polymerase (pol).
The products that are thus obtained by PCR are purified on QuiaAmpยฎ columns and analyzed regarding their size, their degree of purity and their approximate concentration by electrophoresis on agarose gels.
1.2 Genotyping The sequences of nucleotides of the coding regions of the reverse transcriptase are determined by automatic sequencing of the termination of the dideoxynucleotide chain of the crude PCR products.
1.3 Plasmids The molecular clones of the HIV-1 used in the analytical method are derived from pNL4-3.
The plasmid that is deleted by reverse transcriptase is constructed by a
O
(71 modification of the pNL4- 3 xcA e n mut6 to bring unique SnaBI restriction sites into position S3872 and Nru into position 3892.
Enzymes Ba I and SnaB I are used to withdraw the coding region for reverse transcriptase (between positions 2618 and 2872), and the linearization of the resultant (7 plasmid pSRT is carried out by means of the enzyme Nru I. The expression of the envelope glycoprotein VSV-G in the transfected cells is ensured by the pVSV plasmid that contains the coding sequence vsv-g under the monitoring of a CMV promoter.
1.4 Cellular Cultures.
HeLa, 293 T and P4 cells are cultivated in the DMEM medium that is supplemented with 10% fetal calf serum (FCS), 50 UI/ml of penicillin and 50 p.g/ml of streptomycin. The P4 cells are Hela-CD4 and LTR-LacZ cells in which the expression of the beta-galactosidase can be induced only by the transactivating Tat protein of HIV, consequently making possible a precise quantification of infectivity or of the replicative capacity of the HIV-1 viruses based on a unique replication cycle (Charneau, P.; Mirambeau, Roux, Paulous, Buc, H. and Clavel, F. (1994) "HIV-1 Reverse Transcription. A Termination Step at the Center of the Genome." J Mol Biol 241(5), 651-62). The P4 cells are cultivated in the presence of 500 p.g/ml of geneticin.
I
II. Determination of the Susceptibility of an HIV Virus to a Reverse
O
C Transcription (RT) Inhibitor.
The determination of the susceptibility of an HIV virus to a reverse transcriptase Sinhibitor is carried out in the following manner: 293 T cells are transfected with 7.5 Ag of pSRT plasmid that is linearized by NruI, 0.1 ptg of pVSV-G plasmid and 0.5 and 1 pg of the product that is obtained from the PCR reaction of the reverse transcription of HIV.
The transfection precipitate is withdrawn from cells after 18 hours of incubation, and fresh growth medium is added. After 24 hours of cultivation, the supernatant is clarified c by centrifuging (500 g, 15 minutes) and transferred to P4 indicating cells that were preincubated with serial dilutions of a reverse transcriptase inhibitor, in triplicate wells, for four hours. The range of inhibitor concentrations used varies according to the compounds. The signal that is produced by the activation of the marker gene was developed with CPRG for 48 hours as for the analysis of the susceptibility to a reverse transcriptase inhibitor, and index IC 50 was calculated by using the median effect equation.
SII- Optimization of the Analytical Method to Determine the Susceptibility of an HIV Virus to Reverse Transcriptase Inhibitors.
The pSRT plasmid that brings a deletion in the region that codes for pol extending from codon 24 of reverse transcriptase (base 2618) to codon 432 of reverse transcriptase (base 3872) includes all of the mutations combined with a resistance phenomenon that are known to date. The homologous sequences of the reverse transcriptase product obtained from PCR extend 88 base pairs upstream and 186 bases downstream from the deletion in pSRT. The transfections for determining the susceptibility to inhibitors of reverse transcriptase are carried out with a cellular line 293T that has a strong capacity to
O
N be transfected rather than with HeLa cells. This does not constitute a problem because Sthe cells are eliminated from the supernatant that contains the virus by centrifuging 0^ before the transfer of P4 cells.
The transfer conditions are optimized by means of a checkerboard test. The Ci variation of the ratio ofplasmid/product obtained from PCR does not significantly Smodify the amount of p24 or reverse transcriptase produced or the reaction speed with CPRG. Since the circular plasmid, pVSV-G, seems to be extremely toxic for 293T cells, N the amount of the latter was reduced from 3 pg to 0.1 pg in the transfection mixture, leading to high yields of p24 20 ng/ml compared to 9.8 ng/ml).
Since the early phases of the replication of the virus, including the reverse transcription, are produced in P4 indicating cells in this type of determination, these are these cells that are treated with serial dilutions of the reverse transcriptase inhibitors.
The inhibitor concentration ranges that are used are selected based on the cellular toxicity of each compound and the ICo 50
/C
90 ratio for the susceptibility of the resistant isolates (Table For example, since index IC 50 for abacavir for the P4 cells is about 250 uM whereas the IC 50 index for this compound for the native stock of the virus is about 3 p.m, the detection of the resistance is limited by the toxicity. A range of four serial dilutions, beginning at 200 pm, was used for the abacavir, making it possible to detect up to 60x more resistance.
In contrast, since the toxicity of the AZT for the P4 cells is high 300 pjm), whereas the ICso index is considerably lower, a wider range of dilutions was used
I
41 (dilution in a 1/10 series from 5 rpm) so as to allow the detection of high resistance levels
O
1 (up to 100 x).
SFor the reverse transcriptase RVA, the ICso index is used rather than the IC9 index because the detection of the IC 90 index for the resistant viruses could require toxic compound levels for most of the reverse transcriptase inhibitors.
TABLE 1: Susceptibility of Reference Virus NL4-3 to Reverse Transcriptase Inhibitors (RTI).
RT Concentrations of Geometric Standard Maximum Inhibitors Pharmaceutical Agents Mean Deviation a Detectable Used IC 50 a -Susceptibilityb Ranges/Stages of Dilution AZT 50 5nm lox 0.018 pm 2.7 2700 3TC 200 -0.02 ptm lox 1.512 pm 2.2 130 D4T 100 -0.0 1 I lo 0.444 prn 2.7 220 DI100-0.01 jIm lx 1.613 pm 256 Abacavir 20 m 4 x 2.2 m1.8 Efavirenz 10 .1 m 5 x 0.1 m2.2 140 Nevirapine lox 2.0 1300 pm 5nm 0.037 jam A Geometric mean and standard deviation of 20 tests repeated for the reverse transcriptase inhibitors.
B Approximate maximum difference for the IC 5 o and IC 90 indices between NL43 and the tested virus that can be measured by using the given range of pharmaceutical agent concentrations.
The analytical method for determining the susceptibility of the HIV virus to
O
C1 reverse transcriptase inhibitors provides a standard deviation of the geometric mean for tests between 1.78 (abacavir) and 2.7 (D4T and AZT). The median standard deviation for the reverse transcriptase inhibitors (RTI) tested (AZT, 3TC, D4T, DDI, abacavir, efavirenz and nevirapine) is 2.2. To simplify the automatic interpretation of the results (C7 from samples of the patients, an arbitrary Resistance Index (RI) value, RI 5, was defined as the minimum reduction of the susceptibility to an RTI under consideration as being significantly reduced relative to NL43.
"1 To determine if NL43 is a reference virus that is suitable for comparison with clinical isolates, a group of samples taken from patients with ordinary treatment was tested on 3 RVA replicates for their susceptibility to reverse transcriptase inhibitors.
The median IC 5 0 found for 22 tested viruses tends to be slightly higher than the one found for the NL43 virus with an RI media around 0.92 (for stavudine) and 1.22 (lamivudine). Although the RI is less than the defined limit of 5 on the inhibitor total for most of the samples tested, the RI range seems broad, in particular for the non-nucleoside inhibitors. In particular, a resistance index of 11.0 for the nevirapine was obtained for a virus, however, this virus carried a mutation on codon 98 (A for S) of reverse transcriptase, which was previously involved in the resistance to NNRTIs.
IV Reproducibility The reproducibility of the method for determining the susceptibility of the recombinant virus (RVA) to reverse transcriptase inhibitors (RTI) was evaluated by a series of test on 5 samples, selected so as to represent a wide range of susceptibility profiles, between 4 and 8 tests per sample, by using RNA preparations and separate PCR CK1 reactions.
The inter-test variation for determining the susceptibility of the HIV viruses to Sreverse transcriptase inhibitors indicates that in some cases, there is a difference that is greater than 5 between the maximum RI and the minimum RI found for repeated C71 determinations (Table however, the standard deviation of the geometric mean is kept 2.2 in all of the cases except one (R4, AZT). In three of the samples, the RI obtained during repeated tests varies between <5 and >5 for the compounds for which the viruses C can be moderately resistant (RI not higher than 12).
2007249129 19 Dec 2007 Echantillon Index de RMsistanceb (Nombre de G,6notype' tests) AZT I3TC T DDI I Abacavir Efavi rentzNevirapine
RI
(6) 69N/T, 70R MGc scd max/min n>4/N f 1,5 1,5 2,9 1,4 1,4 2,2 1,4 1,6 2,B 1,1 1,2 1,6 1,0 1,1 1,2 2,2 1,8 3,8 1~ 0/6 0/6 0c 1 0/6 0/ 0/6~I r R2 (6) 41L, 62V, 67N, 69N, 751, 77L, 115F,116Y,151M, 181C, 184V, 190A 208Y, 215F, 2190 W 1
MGC
SDd max/mine n>4/N' 1232,6 1,6 3,8 6/6 43,5 2,1 8,1 6/6 26,9 1,7 4,1 6/6 na na 6/6 -74, P 1,7 3, 9 6/6 1,0 1,0 1,0 0/6 184V, 215F
MGC
SD
max/min' f i/N 13,2 2,7 8,9 3,1 1,6 3,3 4,3 1,4 2,4 na na 6/6 1,2 1,3 1,6 0/6 n>4/N t 5/6 1/ 4/6
I
41L, 67N, 69D, 184V, 190A, H208Y, 210W, 215Y 215Y, 41L, 74V, 100j, 103N
MGC
max/ninC n>4"/N'H S o max/mine r f.R
I
137,5 1,8 4,5 3,3 1,6 3,0 'A
J
na na 5/5 1,8 1,7 3,7 3,6 2,0 4,1 3/5 1,7 1,8 3,7 3,0 1,3 1,7 5/5 2,6 1,6 2,5 0/5 .6,1 1,6 3, 3 3/5 1,7 1,6 2, 9 0/5 1 149,8 1,6 3,9 5/5 na na 5/5 na na.
580, 1,8 2,2 n>4iN~ I I I Is5 0/5 0/5 [Key to Table 2:]
O
C1 Echantillon (Nombre de tests) Sample (Number of Tests) Ge6notypea Genotypea Index de R6sistance b Resistance Index b Only the amino acid substitutions already known to be combined with a resistance to reverse transcriptase inhibitors are indicated.
C The Resistance Index is the ratio of IC 5 o in the sample relative to that of NL43 that is determined in parallel.
Geometric mean.
Standard deviation of the geometric mean.
The highest resistance index obtained in the tests divided by the lowest.
The number of tests providing a resistance index 4 classifying the virus as resistant/in the total number of tests carried out.
An IC 5 o above the range that can be detected in all of the tests is indicated by In these cases, a standard deviation and a minimum/maximum are not applicable (na).
The phenotypic results that are obtained for these reverse transcriptase inhibitors show an agreement with the genotypic profiles of the samples.
Sample R2, which shows a high degree of resistance relative to all of the C compounds tested, comprises multiple mutations by including those of the multicompound resistance complex (62V, 751, 77L, 116Y and 151M) that imparts the resistance to RTI nucleotides, the 3TC resistance combined with the 184V mutation and mutations that are known to induce a reduced susceptibility to NNRTI (181C, 190A).
Sample R3 shows a high resistance level at 3TC, again modulated by the mutation 184V, with a considerable variation of the RI for AZT that probably reflects the inconsistent nature of the suppression of the resistance that is induced by 215F by 184V.
C1 In sample R4, such a suppression is thwarted by the presence of multiple mutations including a mutation 208Y.
Sample R5 is kept approximately at AZT despite a mutation 41L and a mutation 215Y because of the effects of the mutation 100I, which, in combination with 103N, is responsible for the high resistance levels observed with regard to efavirenz and nevirapine.
V Validation of the Analytical Method for Determining the Susceptibility of an HIV Virus to Fusion Inhibitors.
The recombinations that are obtained by using for the amplification of stage (b) the pair of primers FuA: 5' AAGCAATGTATGCCCCTCCCAT3' (SEQ ID No: 23) and FuB 5' GGTGGTAGCTGAAGAGGCACAGG3' (SEQ ID No: 24) followed by a second amplification, carried out with the primer FuC ATATGAGGGACAATTGGAGAAGTGA3' (SEQ ID No: 25) and a mixture of the following primers: FuDI 5' TCTGTCTCTCTCTCCACCTTCTTCTT3' (SEQ ID No: 26) and FuD2 5' TCTGTCTTGCTCTCCACCTTCTTCTT3' (SEQ ID No: 27) are very C effective.
O
SActually, to obtain a satisfactory viral production, 10-50 ng of PCR product, used in the recombination stage, is generally adequate. In this method that is intended to analyze the phenotypic fusion characteristic, a viral production corresponding to 50-400 CN ng/ml of p24 is obtained after transfection. For the infection of target cells, between and 5 ng ofp24/well (96-well plates) is used. The increase of the optical density that is obtained after infection of target cells is linear if the infection is conducted under these
O
CN conditions.
To validate the analytical method that relates to the susceptibility of HIV viruses to fusion inhibitors, two fusion inhibitors have been used: a peptide derived from the distal helix sequence in the gp41 of HIV (called DP178 or T20) and a derivative of betulinic acid (RPR103611). For each inhibitor, the reduction of sensitivity of one or more resistant viruses (previously identified by other authors) relative to two reference viruses: a primary plasmatic virus T5A1 and a virus adapted to in-vitro cultivation (LAI) was carried out. All the viruses were produced by recombination.
Results V.1 DP178 or T20 Inhibitor The increases of IC50 for a strongly resistant NL-DIM virus (described by Rimsky, L. T. et al. J. Virol. 1998, Vol. 72, pages 896-993) and for the NL4.3 virus (which is partially resistant) were measured regarding this inhibitor.
The strongly resistant DIM virus exhibits an increase of the value of IC50 by
O
C relative to T5A1 and more than 100x relative to LAI.
SThe partially resistant NL4.3 virus is characterized by an increase of IC50 by 1Ox relative to T5A1 and 12.5x relative to LAI.
C V.1.1 Determination of the Susceptibility of a Plasmatic HIV to the Fusion Inhibitor The viral RNA is extracted from plasmas of HIV-positive patients.
C A first amplification is carried out by PCR with the pair of primers ED3_E01-.
A second amplification is carried out by PCR with the pair of primers E10_FuB to obtain an ADN fragment of 2200 base pairs that extend between residues 6322 and 8522.
The transfection of a first cellular host is carried out with: the nucleic acids that are obtained after the second amplification.
the retroviral vector that is deleted from the entire region that codes for the majority of the gpl20 sub-unit and the extracellular portion of the gp41 of the HIV envelope that extends from residues 6480 to 8263 inclusive and comprises a unique restriction site MluI.
The first cellular host is cultivated under conditions that make it possible to produce viral particles.
The infection is carried out by viral particles that are produced in the preceding stage from a second cellular host (comprising a marker gene that can be activated following viral infection) in the presence of an increasing dose of T20 fusion inhibitor.
The quantification of the marker that is expressed is carried out so as to
O
C,1 demonstrate the level of susceptibility of the HIV viruses that are present in the biological Ssamples to the T20 fusion inhibitor.
SThe results of the phenotypic analysis described above for viruses that are present in plasmas of patients (P1, P2 and P3) and reference viral prototypes (NL43 and resistant C clone DIM) are illustrated in Figure 5, attached, and the IC50 indices are shown in Table 3 below.
C-i Table 3 P1 0.132 P2 0.017 P3 0.047 DIM 3 NL 43 0.234 V.2 RPR103611 Inhibitor The increase of IC50 of the LA1-L91H resistant virus (Labrosse, B. et al. J Virol.
2000 Vol 74, pages 2142-2150) regarding this inhibitor has been measured.
For the LAI-L91H virus, the increase ofIC50 relative to LAI and to T5A1 is greater than 100x.
VI Optimization of the Analytical Method for Determining the
O
Cl NEUTRALIZING CAPACITY of the HIV Viruses The recombinations that are obtained by using for the amplification of stage a pair of primers NEU-A 5' TAGAAAGAGCAGAAGACAGTGGCAATG3' (SEQ ID No: 17) and FuB 5' GGTGGTAGCTGAAGAGGCACAGG3' (SEQ ID No: 24), Cl followed by a second amplification, with the primers NEU-C GTGGGTCACAGTCTATTATGGGG3' (SEQ ID No: 18) and a mixture of primers FuDI 5' TCTGTCTCTCTCTCCACCTTCTTCTT3' (SEQ ID No: 26) and FuD2: N TCTGTCTTGCTCTCCACCTTCTTCTT3' (SEQ ID No: 27) are also very effective.
Actually, during monitoring of viral production, it has turned out that to obtain a satisfactory viral product, generally 10-50 ng of PCR product, used in the recombination stage, is adequate.
A viral production corresponding to 50-400 ng/ml of p24 after transfection is obtained. For the infection of target cells, between 0.5 and 5 ng ofp24/well (96-well plates) is used. The increase in the optical density obtained after infection of target cells is linear if the infection is conducted under these conditions.
VII. Measurement of Viral Infectivity (or Replicative Capacity Test) A first amplification by PCR is carried out with the pair of primers FITA and
PROA-.
A second amplification by PCR is carried out with the pair of primers FITB and PROB- to obtain an ADN fragment of 1488 base pairs that extend between residues 1237 and 2725.
I The transfection of a first cellular host is carried out with: the nucleic acids that are obtained after the second amplification.
the retroviral vector that is deleted from a region that codes for a portion of Gag and the entire protease and that comprises a unique restriction site M uI.
The cultivation of the first cellular host is carried out under conditions that make it possible to produce viral particles.
The amount of recombinant viral particles is measured in the supernatant of this culture by an Elisa test metering the amount of p24 antigen.
The infection is carried out by the viral particles that are produced in the preceding stage from a second cellular host (comprising a marker gene that can be activated following viral infection) by increasing dilutions of viral supemrnatant.
The quantification of the marker that is expressed to demonstrate the infectivity level of the recombinant virus is carried out.
The replicative capacity of the recombinant virus is calculated by plotting a straight regression line from the measured values and by adopting the slope of this straight line.
The viral replicative capacity is expressed relative to that of a reference laboratory virus or relative to the recombinant virus that carries viral sequences that are obtained from the same patient before establishing treatment and before development of the resistance. The results that are obtained are illustrated in Figure 6, attached.
The L1, L2 and L3 viruses correspond to recombinant viruses that carry protease sequences that are obtained at three different moments from the same patient. The L1 virus carries protease sequences that are obtained before treatment. Each point 53 corresponds to the optical density that is measured after infection of P4 indicating cells
O
C, by a dilution of each of the 3 viruses. A straight line of regression is traced for the series Sof measurements of each virus. The slope of the straight line is calculated. The replicative capacity of L2 is expressed relative to the slope of L2 to that of LI, and the replicative capacity of L3 by the ratio of the slope of L3 to that of L1. Here, the CK, reference virus is the pretherapeutic virus LI. When the pretherapeutic virus is lacking, it is possible to express the replicative capacity of a patient virus relative to a reference laboratory virus such as pNL4-3.
Claims (31)
1. Method for analysis of a phenotypic characteristic of HIV viruses that 0are present in a biological sample from a patient, whereby said phenotypic characteristic results from one or more mutations of the viral genome that can influence the viral infection, characterized in that it comprises: a) The extraction of nucleic acids that are contained in said biological sample, b) at least one amplification by PCR of a segment of the nucleic acids of O stage each with a pair of primers that frame a nucleic acid sequence of the viral genome that can carry at least one mutation, c) the preparation of a vector that comprises the parts of a genome of an HIV virus that are necessary for the viral replication except for the amplified segment in stage and optionally with the exception of the is gene that codes for the envelope protein, d) the transfection of a first cellular host with: The nucleic acids that are obtained in stage The vector that is prepared in stage Optionally a second vector that comprises a gene that codes for an envelope protein if the envelope gene is deleted from the vector that is prepared in stage to obtain a chimerical virus by homologous recombination, e) the culture of said first cellular host under conditions that make it possible to produce viral particles during a single replication cycle, f) the infection by the viral particles that are obtained in stage from at least a second cellular host that can be infected by an HIV virus or an HIV-pseudotype virus and that optionally comprises a marker gene that can be activated only following viral infection, g) the detection and/or the quantification of the marker that is expressed in stage so as to demonstrate at least one characteristic of the HIV viruses that are present in the biological sample. N \Mclboure\Cascs\Patent400049999\P49475.AU I\Spccis\P4!475 AU.I Spccification 2007-i2-17.doc 19/12/07 p' 55 O 0 2. Analytical method according to claim 1, wherein amplification by PCR 0 of stage is carried out with a pair of primers that frame a nucleic acid sequence that Scomprises all or part of a viral genome region that is selected from among: gag, pol, protease, reverse transcriptase, RNAse H, integrase, vif, vpr, tat, rev, vpu, env, nef, cis-active sequences, LTR, dimerization sequences, splicing-regulating sequences or the Rev response element (RRE).
3. Analytical method according to any of claims 1 or 2, wherein the amplification by PCR of stage is carried out with a pair of primers that frame a O 10 nucleic acid sequence that codes for a portion of the gag protein of the human immunodeficiency virus and a nucleic acid sequence that codes for the protease that can carry at least one mutation in the gene that codes for the protease and wherein the vector of stage is constructed from a genome of an HIV virus where all or part of the gene that codes for the protease is deleted.
4. Analytical method according to claims 1 to 3, wherein the amplification of stage that carries at least one mutation in the gene that codes for the protease is made with a pair of primers: Fit A TCA CCT AGA ACT TTA AAT GC (SEQ ID No: l)and Pro A GGC AAA TAC TGG AGT ATT GTA TG3') (SEQ ID No: 2), followed by a second amplification, with a pair of primers: Fit B AGA ACT TTA AAT GCA TGG GT (SEQ ID No: 3) and Pro B GGA GTA TTG TAT GGA TTT TCA GG3') (SEQ ID No: 4), to obtain an ADN segment of 1488 base pairs that extend between residues 1237 and 2725 inclusive, and wherein the vector of stage is a retroviral vector that is deleted from the region of the pol reading frame that codes for the HIV-1 protease that extends from residues 1505 to 2565 inclusive, deleted from the envelope region and comprising a unique restriction site Mlul. Analytical method according to claim 1 or 2, wherein the amplification by PCR of stage is carried out with a pair of primers that frame a nucleic acid N:\Melboume\Cases\Patnt\49000-49999\P49475 AU I\Specis\P4947S AU. I Spccicaion 2007- 2-17doc 19/12/07 56 O O sequence that can carry at least one mutation in the gene that codes for the reverse Stranscriptase, and the transfection of stage is carried out with a first vector that is constructed from a genome of an HIV virus where all or part of the gene that codes for the reverse transcriptase is deleted.
6. Analytical method according to claim 1, 2 or 5, wherein the amplification of stage is carried out with a pair of primers: MJ3 AGT AGG ACC TAC ACC TGT CA (SEQ ID No: 5) and RT-EXT TTC CCA ATG CAT ATT GTG AG (SEQ ID No: 6), followed by a second amplification stage with a pair of primers: TTG GTT GCA TAA ATT TTC CCA TTA GTC CTA TT (SEQ ID No: 7) and RT-IN TTC CCA ATG CAT ATT GTG AG (SEQ ID No: 8) to obtain an ADN segment of 1530 base pairs that extend beyond codon 93 of the region that codes for the protease and beyond codon 503 of the region that codes for the polymerase (POL), and wherein the vector of stage is a retroviral vector that is deleted from the region of the pol reading frame that codes for the HIV-1 reverse transcriptase that extends from residues 2618 to 2872 inclusive and comprises a unique restriction site MluI.
7. Analytical method according to claim 1 or 2, wherein the amplification by PCR of stage is carried out with a pair of primers that frame a nucleic acid sequence that codes for a portion of the gag protein, for the protease and for a portion of the reverse transcriptase of the human immunodeficiency virus that can carry at least one mutation in the nucleic acid sequence that codes for the gag protein or for the protease or for the reverse transcriptase.
8. Analytical method according to claim 1, 2 or 7, wherein the amplification of stage is carried out with the pair of primers: gag+l AGGGGCAAATGGTACATCA (SEQ ID No: 31) and RT-EX (SEQ ID No: 6), N WelbourneNCases\PatI\490O-49999\P49475AU \Specis\P49475AU I Specification 2007-12-17doc 19/12107 57 O O followed by a second amplification stage with a pair of primers: SFit B+ (SEQ ID No: 1) and SRT-IN (SEQ ID No: 8) to obtain an ADN segment of 2825 base pairs that extend between residues 1237 and 4062 and wherein the transfection of stage is carried out with a retroviral vector that is deleted from a portion of the gag gene and regions within the pol reading frame that codes for the protease and a portion of the HIV-1 reverse transcriptase that extends from residues 1507 to 3870 inclusive, deleted in the envelope region and comprising a unique restriction site NruI.
9. Analytical method according to claims 1, 2, 5 or 6 that consists in determining the susceptibility of an HIV virus to an inhibitor compound of reverse transcriptase, wherein said inhibitor compound of reverse transcriptase, optionally at different concentrations, is added or not added to the second cellular host, prior to the infection of the latter by viral particles that are obtained in stage and wherein stage comprises the comparison of the expression of the marker gene with and without an inhibitor compound of the reverse transcriptase.
10. Analytical method according to claim 1 or 2, win the amplification by PCR of stage is carried out with a pair of primers that frame a nucleic acid sequence that can carry at least one mutation in the gene that codes for integrase, and the vector of stage is a retroviral vector that is deleted from all or part of the gene that codes for integrase.
11. Analytical method according to claim 1, 2 or 10, wherein the amplification of stage is carried out with the pair of primers: INT B+ 5' GTTACTAATAGAGGAAGACAAA3' (SEQ ID No: 9) and INT B- 5' TTTTGGTGTTATTAATGCT3' (SEQ ID No: followed by a second amplification stage, with the pair of primers: INT V+ 5' CACCCTAACTGACACAACAA3' (SEQ ID No: 11) and INT V- 5' AAGGCCTTTCTTATAGCAGA3' (SEQ ID No: 12), N:\Melboume\Case\Paent\A9000-49999\P49475 AU I\Spcis\P49475.AU I Speciialcon 2007-12-17doc 9/12/07 58 O O to obtain an ADN fragment of 1460 base pairs that extend from residues 3950 to S5410 inclusive, Swherein the vector of stage is a retroviral vector that is deleted from the entire region of the pol reading frame that codes for the HIV-1 integrase that extends s from residues 4228 to 5093 inclusive and from the region that codes for the viral envelope between positions 6343 and 7611 inclusive.
12. Analytical method according to claim 1, 2, 10 or 11 that consists in determining the susceptibility of an HIV virus to an inhibitor compound of the integrase, consisting in adding or not adding said inhibitor compound of the integrase, optionally at different concentrations, during stage before stage and wherein stage comprises the comparison of the expression of the marker gene with and without an inhibitor compound of the integrase.
13. Analytical method according to claim 1 or 2, wherein the amplification by PCR of stage is carried out with a pair of primers that frame a nucleic acid sequence that can carry at least one mutation in the gene that codes for the envelope protein, and wherein the vector of stage is a retroviral vector that is constructed from a genome of an HIV virus where all or part of the gene that codes for the envelope protein is deleted.
14. Analytical method according to claim 1, 2 or 13, wherein the vector of stage is a retroviral vector that is deleted from the entire region that codes for the extracellular portion of sub-unit gp41 of the HIV-1 envelope that extends from residues 7745 to 8263 inclusive, from the region of the HIV-1 genome that constitutes the Rev response element (RRE). Analytical method according to claim 1, 2, 13 or 14, wherein the amplification of stage is carried out with a pair of primers: FIN-A: 5' TCAAATATTACAGGGCTGCT3' (SEQ ID No: 13) and FIN-B: 5' TAGCTGAAGAGGCACAGG3' (SEQ ID No: 14) followed by a second amplification stage, carried out with the pair of primers: N 1ebourne\Cas'\Patent\49000-49999\P4947SAU. I\Spccis\P4947.AU. I Specification 2007-12-17 doc 19/12/07 59 O FIN-C: 5' CTATTAACAAGAGATGGTGG3' (SEQ ID No: 15) and O FIN-D: 5' TCCACCTTCTTCTTCGATT3' (SEQ ID No: 16), to obtain an ADN segment of 965 base pairs that extend from residues 7553 to 8517 inclusive and wherein the vector of stage is a retroviral vector that is deleted from the entire region that codes the extracellular portion of sub-unit gp41 of the HIV-1 envelope that extends from residues 7745 to 8263 inclusive and comprises a unique restriction site Mull. So 16. Analytical method according to claim 1, 2, 13 or 14, wherein the amplification of stage with a pair of primers that frame a nucleic acid sequence that can carry at least one mutation in the gene that codes for the envelope protein is made with a pair of primers: FuA: 5' AAGCAATGTATGCCCCTCCCAT3' (SEQ ID No: 23) and is FuB: 5' GGTGGTAGCTGAAGAGGCACAGG3' (SEQ ID No: 24), followed by a second amplification stage, carried out with the primer: FuC': 5' ATATGAGGGACAATTGGAGAAGTGA3' (SEQ ID No: and a mixture of the following primers: TCTGTCTCTCTCTCCACCTTCTTCTT3' (SEQ ID No: 26) and FuD2: 5' TCTGTCTTGCTCTCCACCTTCTTCTT3' (SEQ ID No: 27), whereby said mixture is preferably carried out in a ratio of between (10% and (90% 10%) and quite preferably between (60% 40%) and (40% to obtain an ADN segment of 805 base pairs that extend from residues 7635 to 8440 inclusive, and the vector stage is a retroviral vector that is deleted from the entire region that codes for the extracellular portion of sub-unit gp41 of the HIV-1 envelope that extends from residues 7745 to 8263 inclusive and comprises a unique restriction site Mul 1.
17. Analytical method according to claim 1,2, 13 or 14, wherein the amplification of stage is carried out with a pair of primers: NEU-A 5' TAGAAAGAGCAGAAGACAGTGGCAATG3' (SEQ ID No: 17) and N MIlboume\Cses\P.,cnt\4900O-49999P4475 AU I\Spccis\P49475 AU I Sprification 2007-2-17dm 19/12/07 60 O O FIN-B 5' TAGCTGAAGAGGCACAGG3' (SEQ ID No: 14), followed by a Ssecond amplification stage, with the pair primers: Q NEU-C 5' GTGGGTCACAGTCTATTATGGGG3' (SEQ ID No: 18) and FIN-D 5' TCCACCTTCTTCTTCGATT3' (SEQ ID No: 16), s to obtain an ADN fragment of between 2106 and 2320 base pairs that extend from residues 6197-6222 up to residues 6197-6222 inclusive and wherein the vector of stage is a retroviral vector that is deleted from the entire region that codes for the majority of sub-unit gpl20 and the extracellular portion of gp41of the HIV-I envelope that extends from residues 6480 to 8263 inclusive and 0 10 comprises a unique restriction site Mlul.
18. Analytical method according to claim 1, 2, 13 or 14, wherein the amplification of stage with a pair of primers that frame a nucleic acid sequence that can carry at least one mutation in the gene that codes for the envelope protein is made with a pair of primers: NEU-A 5' TAGAAAGAGCAGAAGACAGTGGCAATG3' (SEQ ID No: 17) and FuB 5' GGTGGTAGCTGAAGAGGCACAGG3' (SEQ ID No: 24), followed by a second amplification stage, with the primers: NEU-C 5' GTGGGTCACAGTCTATTATGGGG3' (SEQ ID No: 18) and a mixture of the primers FuDI 5' TCTGTCTCTCTCTCCACCTTCTTCTT3' (SEQ ID No: 26) and FuD2 5' TCTGTCTTGCTCTCCACCTTCTTCTT3' (SEQ ID No: 27), whereby said mixture is preferably carried out in a ratio that is between (10% 90%) and (90% 10%) and quite preferably between (60% 40%) and (40% to obtain an ADN fragment of 2118 base pairs that extend from residues 6322 to 8440 inclusive, and the vector of stage is a retroviral vector that is deleted from the entire region that codes for the majority of sub-unit gpl20 and the extracellular portion of the gp41 of the HIV-1 envelope that extends from residues 6480 to 8263 inclusive and comprises a unique restriction site Mul1.
19. Analytical method according to claim 1,2, 13 or 14, wherein the N \1Ielboume\Cascs\Paten\49000-49999\P49475 AU I\Specis\P49475AU I Specificaion 2007-2-I17Ado I9112107 61 O O amplification of stage with a pair of primers that frame a nucleic acid sequence that Scan carry at least one mutation in the gene that codes for the envelope protein is made Swith the pair of primers: ED3 5' TTAGGCATCTCCTATGGCAGGAAGAAGCGG3' (SEQ ID No: 28) and E01 5' TCCAGTCCCCCCTTTTCTTTTAAAAA3' (SEQ ID No: 29), followed by a second amplification stage, with the primers: 5' GTGGGTCACAGTCTATTATGGGGT3' (SEQ ID No: 30) and FuB 5' GGTGGTAGCTGAAGAGGCACAGG3' (SEQ ID No: 24) to obtain an ADN fragment of 2200 base pairs that extend from residues 6322 to 8522 inclusive, and the vector of stage is a retroviral vector that is deleted from the entire region that codes for the majority of sub-unit gpl20 and the extracellular portion of the gp41 of the HIV-1 envelope that extends from residues 6480 to 8263 inclusive and comprises a unique striction site Mul1. Analytical method according to claim 1, 2, 13 or 14, wherein the amplification of stage is carried out with a pair of primers: EOO 5' TAGAAAGAGCAGAAGACAGTGGCAATGA3' (SEQ ID No: 19) and ES8B 5' CACTTCTCCAATTGTCCCTCA3' (SEQ ID No: followed by a second amplification stage with the pair of primers: 5' GGGCCACACATGCCTGTGTACCCACAG3' (SEQ ID No: 21) and 5' AGAAAAATTCCCCTCCACAATTAA3' (SEQ ID No: 22), to obtain an ADN segment of 938 base pairs that extend from residues 6426 to 7364 inclusive, and wherein the vector of stage is a retroviral vector that is deleted from the region, coding for the domains that extend from loop VI to loop V3 of the HIV-I envelope that extends from 6617 to 7250 inclusive and comprises a unique restriction site NheI.
21. Analytical method according to claims 1, 2, and 13 to 20 that consists in determining the susceptibility of an HIV virus to a fusion-inhibitor compound that N \lcelboume\Cascs\Pren\49OO49999\P4O475 AU \Specis\P49475AU.1 Specifiction 2007-12.1 Idoc 19/12/07 62 targets the gp41 protein of HIV-1, wherein said fusion-inhibitor compound, optionally N at different concentrations, is added during the cultivation of the cellular host that is ยข3 Sobtained in stage before stage and wherein stage comprises the comparison of the expression of the marker gene with and without a fusion-inhibitor compound targeting the gp41 of HIV- 1.
22. Analytical method according to claim 1, 2, 13, 14 or 16 that consists in determining the susceptibility of an HIV virus to compound that inhibits the entry of said HIV virus into a target cell, wherein said compound that inhibits entry, optionally 1o at different concentrations, is added to the cellular host that is obtained in stage (e) before the infection of stage and wherein stage comprises the comparison of the expression of the marker gene with and without a compound that inhibits entry.
23. Analytical method according to claim 1, 2, 13, 14 or 17 consisting in determining the susceptibility of an HIV virus to the inhibiting action of antibodies, wherein said method is carried out, on the one hand, without antibodies, and, on the other hand, with antibodies, optionally at different concentrations, whereby said antibodies are present in stage and wherein stage comprises the comparison of the expression of the marker gene with and without antibodies.
24. Analytical method according to claim 1,2, 13, 14 or 17 that consists in determining the tropism of an HIV virus for a cellular receptor, wherein the infection of stage with the viral particles that are obtained in stage is carried out on two separate cellular hosts, and stage comprises the comparison of the expression of the marker gene by each of the two separate cellular hosts. Analytical method according to claim 24, wherein one of the two cellular hosts infected in stage expresses receptor CCR5 and the other expresses the receptor CXCR4.
26. Analytical method according to claim 1,2, 13, 14 or 17 that consists in determining the susceptibility of an HIV virus to an inhibitor compound that targets the N \Melboume\Csses\Patent\49000-49999\P49475 AU. I \Spccis\P49475AU I Specification 2007.12-17 doc 19/12/07 63 O O co-receptors of HIV-1, wherein said inhibitor compound that targets the co-receptors of SHIV-1, optionally at different concentrations, is added or not added during cultivation stage wherein the infection of stage is carried out on two separate cellular hosts and wherein stage comprises the comparison of the expression of the marker gene by each of the two separate cellular hosts.
27. Analytical method according to claim 1, 2, 13, 14 or 20 that consists in analyzing the tropism of an HIV virus for a cellular receptacle, wherein the infection of stage with the viral particles that are obtained in stage is carried out on two separate cellular hosts, and stage comprises the comparison of the expression of the marker gene by each of the two separate cellular hosts.
28. Analytical method according to 1, 2, 13, 14 or 20 that consists in analyzing the susceptibility of an HIV virus to an inhibitor compound that targets the co-receptors of HIV-1, wherein said inhibitor compound that targets the co-receptors of HIV-1, optionally at different concentrations, is added during the cultivation of stage wherein the infection of stage with the viral particles that are obtained in stage is carried out on two separate cellular hosts and wherein stage comprises the comparison of the expression of the marker gene by each of the two separate cellular hosts.
29. Analytical method according to any of claims 1 to 20 that consists in determining the infectivity or the replicative capacity of an HIV virus, wherein stage (g) comprises the comparison of the expression of the marker gene by the second cellular host that is infected with the viral particles that are obtained by applying stages to (f) to a biological sample of a patient, and the expression of the marker gene by the same second cellular host infected with reference viral particles that are obtained by applying stages to to a sample that contains a reference virus.
30. Analytical method according to claim 29, wherein the reference viral particles that are obtained from a reference virus are viral particles that are obtained by the application of stages to to a biological sample of the same patient at a N \Mclboumc\Case\Paent\49000-49999\P49475 AU I\SpCciS\P49475.AU. I Speciicalion 2007-12-17doc 19/1 2/07 64 previous stage of the therapeutic treatment or before the latter.
31. Analytical method according to claims 1 to 20 that consists in determining the susceptibility of an HIV virus to hydroxyurea, wherein hydroxyurea, optionally at different concentrations, is added or not added either during cultivation stage or to the second cellular host, before the infection of the latter in stage and wherein stage comprises the comparison of the expression of the marker gene with and without hydroxyurea.
32. Analytical method according to any of claims 1 to 31, wherein cultivation stage is carried out during a period from 12 hours to 72 hours, preferably 24 hours to 48 hours.
33. A kit for the implementation of a method according to any of claims 1 to is 32, wherein it comprises: i. A pair of primers that frame a nucleic acid sequence of the viral genome that can carry at least one mutation, ii. a vector that comprises the parts of a genome of an HIV virus that are necessary to the viral replication except for the segment amplified with the primers that are defined by and the gene that codes for the envelope protein, iii. a second vector that comprises a gene that codes for an envelope protein, iv. a first cellular host that can be infected by an HIV virus, v. a second cellular host that can be infected by an HIV virus and that comprises a marker gene that can be activated only following viral infection, vi. the products and reagents necessary for carrying out the amplification by PCR, vii. the products and reagents that make it possible to detect the expressed marker.
34. A kit according to claim 33, wherein it comprises: N Melbourne\Cases\Paen\49OOO4999D\P49475 AU I\Specis\P4475AU. I Specification 2007-12-17doc 19/12107 65 O i. The sequence primer pairs: SEQ ID No: 1 and SEQ ID No: 2 SEQ ID No: 3 and SEQ ID No: 4 ii. a retroviral vector that is deleted from the region of the pol reading frame s that codes for the HIV-1 protease that extends from residues 1505 to 2565 inclusive, deleted from the envelope region and comprising a unique restriction site M 1 ul, iii. a pseudotype virus with a gene that codes for an envelope virus, iv. a first cellular host that can be infected by an HIV virus, v. a second cellular host that can be infected by an HIV virus and that comprises a marker gene that can be activated only following viral infection, vi. the products and reagents that are necessary for carrying out the amplification by PCR, vii. the products and reagents that make it possible to detect the expressed marker. A kit according to claim 33, wherein it comprises: i. the sequence primer pairs: SEQ ID No: 5 and SEQ ID No: 7 SEQ ID No: 6 and SEQ ID No: 8 ii. a retroviral vector that is deleted from the region of the pol reading frame that codes for the HIV-1 reverse transcriptase that extends from residues 2618 to 2872 inclusive and that comprises a unique restrictions site MluI, iii. a virus that is pseudotyped by a gene that codes for an envelope protein, iv. a first cellular host that can be infected by an HIV virus, v. a second cellular host that can be infected by an HIV virus and that comprises a marker gene that can be activated only following viral infection, vi. the products and reagents that are necessary for carrying out the amplification by PCR, N \Mcboume\Case\PateI\49000-49999P49475 AU I\Spccis\P49475AU I Specica:ion 2007-I2-17doc 9/12/07 66 O vii. the products and reagents that make it possible to detect the expressed marker.
36. A kit according to claim 33, wherein it comprises: s i. the sequence primer pairs: SEQ ID No: 9 and SEQ ID No: SEQ ID No: 11 and SEQ ID No: 12 ii. a retroviral vector that is deleted from the entire region of the pol reading frame that codes for the HIV-1 integrase that extends from residues 4228 to 5093 inclusive and the region that codes for the viral envelope between positions 6343 and 7611 inclusive, iii. a virus that is pseudotyped by a gene that codes for an envelope protein, iv. a first cellular host that can be infected by an HIV virus, v. a second cellular host that can be infected by an HIV virus and that is comprises a marker gene that can be activated only following viral infection, vi. the products and reagents that are necessary for carrying out the amplification by PCR, vii. the products and reagents that make it possible to detect the expressed marker.
37. A kit according to claim 33, wherein it comprises: i. the sequence primer pairs: SEQ ID No: 13 and SEQ ID No: 14 SEQ ID No: 15 and SEQ ID No: 16 ii. a retroviral vector that is deleted from the entire region that codes for the extracellular portion of sub-unit gp41 of the HIV-1 envelope that extends from residues 7745 to 8263 inclusive and comprises a unique restriction site Mull, iii. a virus that is pseudotyped by a gene that codes for an envelope protein, iv. a first cellular host that can be infected by an HIV virus, v. a second cellular host that can be infected by an HIV virus and that N \Melboume\Cases\Patent\49 0004999949475AU. I\Specis\P49475AU I Spcciication 2007-12-17 doc 19/I2/07
67- O O comprises a marker gene that can be activated only following viral O infection, vi. the products and reagents that are necessary for carrying out the amplification by PCR, vii. the products and reagents that make it possible to detect the expressed marker. 38. A kit according to claim 33, wherein it comprises: Si. the sequence primer pairs: SEQ ID No: 23 and SEQ ID No: 24 SEQ ID No: 25 and SEQ ID No: 26 with SEQ ID No: 27 ii. a retroviral vector that is deleted from the entire region that codes for the extracellular portion of sub-unit gp41 of the HIV-1 envelope that extends from residues 7745 to 8263 inclusive and comprises a unique restriction site Mull, iii. a virus that is pseudotyped by a gene that codes for an envelope protein, iv. a first cellular host that can be infected by an HIV virus, v. a second cellular host that can be infected by an HIV virus and that comprises a marker gene that can be activated only following viral infection, vi. the products and reagents that are necessary for carrying out the amplification by PCR, vii. the products and reagents that make it possible to detect the expressed marker. 39. A kit according to claim 33, wherein it comprises: i. the sequence primer pairs: SEQ ID No: 17 and SEQ ID No: 14 SEQ ID No: 18 and SEQ ID No: 16 ii. a retroviral vector that is deleted from the entire region that codes for the majority of sub-unit gpl20 and the extracellular portion of the gp41 of the HIV-I envelope that extends from residues 6480 to 8263 inclusive N \Meboure\Cawse\Patcnt49000-49999\P49475 AU I\Spccis\P49475AU.I Specification 2007-12-l7doc 1911207 68 O O and comprises a unique restriction site Mul 1, 0 iii. a virus that is pseudotyped by a gene that codes for an envelope protein, iv. a first cellular host that can be infected by an HIV virus, v. a firstecond cellular host that can be infected by an HIV virus and that 0v. a second cellular host that can be infected by an HIV virus and that comprises a marker gene that can be activated only by viral particles, vi. the products and reagents that are necessary for carrying out the amplification by PCR, vii. the products and reagents that make it possible to detect the expressed marker. 010 0 io A kit according to claim 33, wherein it comprises: i. the sequence primer pairs: SEQ ID No: 17 and SEQ ID No: 24 SEQ ID No: 18 and SEQ ID No: 26 with SEQ ID No: 27 is ii. a retroviral vector that is deleted from the entire region that codes for the majority of sub-unit gpl20 and the extracellular portion of the gp41 of the HIV-1 envelope that extends from residues 6480 to 8263 inclusive and comprises a unique restriction site Mul 1, iii. a virus that is pseudotyped by a gene that codes for an envelope protein, iv. a first cellular host that can be infected by an HIV virus, v. a second cellular host that can be infected by an HIV virus and that comprises a marker gene that can be activated only by viral particles, vi. the products and reagents that are necessary for carrying out the amplification by PCR, vii. the products and reagents that make it possible to detect the expressed marker. 41. A kit according to claim 33, wherein it comprises: i. the sequence primer pairs: SEQ ID No: 19 and SEQ ID No: SEQ ID No: 21 and SEQ ID No: 22 ii. a retroviral vector that is deleted from the region, coding for the domains N \Mebourn\Caseatent\490OO999\P4947AU. I\Speci\P4975 AU. I Specificaion 2007-12-17.doc 19/1107 69 O that extend from loop VI to loop V3 of the HIV-1 envelope that extends O from 6617 to 7250 inclusive and that comprises a unique restriction site SNheI, iii. a virus that is pseudotyped by a gene that codes for an envelope protein, s iv. a first cellular host that can be infected by an HIV virus, v. a second cellular host that can be infected by an HIV virus and that comprises a marker gene that can be activated only following viral infection, vi. the products and reagents that are necessary for carrying out the amplification by PCR, vii. the products and reagents that make it possible to detect the expressed marker. 42. A kit according to claim 33, wherein it comprises: i. the sequence primer pairs: SEQ ID No: 5 and SEQ ID No: 6 SEQ ID No: 7 and SEQ ID No: 8 ii. a retroviral vector that is deleted from the region of the pol reading frame that codes for the HIV-1 reverse transcriptase that extends from residues 2618 to 2872 inclusive and comprises a unique restriction site MluI, iii. a virus that is pseudotyped by a gene that codes for an envelope protein, iv. a first cellular host that can be infected by an HIV virus, v. a second cellular host that can be infected by an HIV virus and that comprises a marker gene that can be activated only following viral infection, vi. the products and reagents that are necessary for carrying out the amplification by PCR, vii. the products and reagents that make it possible to detect the expressed marker. 43. A kit according to claim 33, wherein it comprises: i. the sequence primer pairs: N:\Mclboumre\Cases\Patent\49000-49999\P49475 AU I\Specis\P49475 AU I Spocificaion 2007-12-17doc 19/12/07 S- 70 O SEQ ID No: 28 and SEQ ID No: 29 and 0 SEQ ID No: 30 and SEQ ID No: 24 ii. a retroviral vector that is deleted from the entire region that codes for the Smajority of sub-unit gpl20 and the extracellular portion of the gp41 of the HIV-1 envelope that extends from residues 6480 to 8263 inclusive and comprises a unique restriction site Mul 1, iii. a virus that is pseudotyped by a gene that codes for an envelope protein, iv. a first cellular host that can be infected by an HIV virus, v. a second cellular host that can be infected by an HIV virus and that comprises a marker gene that can be activated only following viral infection, vi. the products and reagents that are necessary for carrying out the amplification by PCR, vii. the products and reagents that make it possible to detect the expressed marker. N:\MelboumeNCases\Patenl4900-49999\P4947A I\Specis\P49475.AU. Specification 2007-1217 doc 19/12107
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2007249129A AU2007249129A1 (en) | 2000-11-10 | 2007-12-19 | Novel method for analysing phenotypic characteristics of human immunodeficiency virus (HIV) |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR00/14495 | 2000-11-10 | ||
| FR01/03970 | 2001-03-23 | ||
| US09/817,135 | 2001-03-27 | ||
| AU2002223052A AU2002223052B2 (en) | 2000-11-10 | 2001-11-09 | Novel method for analysing phenotypic characteristics of human immunodeficiency virus (HIV) |
| AU2007249129A AU2007249129A1 (en) | 2000-11-10 | 2007-12-19 | Novel method for analysing phenotypic characteristics of human immunodeficiency virus (HIV) |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002223052A Division AU2002223052B2 (en) | 2000-11-10 | 2001-11-09 | Novel method for analysing phenotypic characteristics of human immunodeficiency virus (HIV) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2007249129A1 true AU2007249129A1 (en) | 2008-01-24 |
Family
ID=38984364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2007249129A Abandoned AU2007249129A1 (en) | 2000-11-10 | 2007-12-19 | Novel method for analysing phenotypic characteristics of human immunodeficiency virus (HIV) |
Country Status (1)
| Country | Link |
|---|---|
| AU (1) | AU2007249129A1 (en) |
-
2007
- 2007-12-19 AU AU2007249129A patent/AU2007249129A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008022861A (en) | Novel method for analyzing phenotypic characteristics of human immunodeficiency virus (hiv) | |
| Walter et al. | Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors | |
| Wei et al. | Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy | |
| Zack et al. | HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure | |
| Shi et al. | A recombinant retroviral system for rapid in vivo analysis of human immunodeficiency virus type 1 susceptibility to reverse transcriptase inhibitors | |
| US7235356B2 (en) | Methods of evaluating cell surface receptor binding of a patient derived population of viral envelope protein constructs | |
| US7097970B2 (en) | Methods of evaluating viral entry inhibitors using patient derived envelope protein constructs | |
| US8076062B2 (en) | Mutational profiles in HIV-1 protease correlated with phenotypic drug resistance | |
| MXPA00011623A (en) | Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy. | |
| WO2003070985A1 (en) | Compositions and methods for evaluating viral receptor/co-receptor usage and inhibitors of virus entry using recombinant virus assays | |
| US20070269797A9 (en) | Method for analysis of the phenotypic characteristics of the human immunodeficiency virus (HIV) | |
| US20020123036A1 (en) | Method for analysing human immunodeficiency virus (HIV) phenotypic characteristics | |
| AU2007249129A1 (en) | Novel method for analysing phenotypic characteristics of human immunodeficiency virus (HIV) | |
| Ballard et al. | HIV drug resistance: genotypic assays and their possible applications | |
| US20050214744A1 (en) | New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance | |
| EP1520036B1 (en) | New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance | |
| US20050059033A1 (en) | Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS | |
| EP1402076A2 (en) | Compositions and methods for evaluating viral receptor/co-receptor usage and inhibitors of virus entry using recombinant virus assays | |
| Weissbrich et al. | Evaluation of drug resistance in HIV infection | |
| US20020094522A1 (en) | Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS | |
| FR2829505A1 (en) | Analyzing phenotypic characteristics of human immune deficiency virus, useful for assessing susceptibility to hydroxyurea of virus with mutated reverse transcriptase gene | |
| FR2829501A1 (en) | Analyzing phenotypic characteristics of human immune deficiency virus, useful e.g. for assessing infective or replicative capacity or susceptibility to viral inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |